An investigation of the potential anti-diabetic (insulinomimetic) activity of anti-oxidant compounds derived from Sargassum heterophyllum by Nyambe, Mutenta Nsokolo
  
An Investigation of the Potential Anti-diabetic 
(insulinomimetic) Activity of Anti-oxidant 
Compounds Derived from Sargassum 
heterophyllum 
 
 
A Thesis Submitted in Fulfilment of the Requirements for the 
degree of 
 
 
Master of Science (Pharmacy) 
Rhodes University 
 
 
By 
 
Mutenta Nsokolo Nyambe 
August 2013 
 
 
 
  
 
 
 
 
 
 
In dedication to my late mother, Christine Nsokolo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
Acknowledgements 
 
Firstly, I would like to thank my supervisor, Dr. Denzil Beukes, for his incessant belief in me 
and in the project as well as for his continuous and sufficient guidance throughout this 
research. Without his expertise, this project would not have been the success that it now is. I 
would also like to thank my co-supervisor, Dr. Leonie Goosen for her concerted efforts in 
ensuring that I was always motivated to work harder past my failures, mistakes and 
challenges. 
The success of this research is also indebted to the significant contributions of various 
organizations and individuals. Amongst such, I would like to express my gratitude towards 
the following: 
 The Beit Trust Scholarship for funding my entire research 
 Prof. Maryna Van De Venter and Dr. Trevor Koekemoer from Nelson Mandela 
Metropolitan University for in-vitro assays 
 Dr. Pierre Kempgens for assistance with NMR experiments 
 Candice L. Bromley for assistance with HPLC experiments 
 The Rhodes University Faculty of Pharmacy technical stuff; Mr and Mrs Morley, Ms 
Prudence Mzangwa and Mr Tich Samkange for technical support 
 Ms Catherine Luyt, Drs Roman Tandlich, Bhupesh Samant, Kasongo Wa Kasongo 
and Anthonia Afolayan for moral support and advise 
 The Rhodes Faculty of Pharmacy staff and post-graduate students for their support 
 Mr. Gift M. Nyambe for proof reading this thesis 
 Ms Ayeshah Fauzee for the moral support and timely assistance 
 My Napromed research group: Ms Tatenda Munedzimwe, Mr Maynard Chiwakata, 
Mr Jameel Fakee, Mr Denzel Mubare and Mr Byron Mubaiwa. Thank you for making 
this challenging journey so bearable and worthwhile 
 My G3 lab mates: Ms Chikomborero Chakaingesu, Mr Theonesté Umumararungu and 
Olubomehin Oseyemi for moral support 
 Ms Winjie Siwale, Mr. Chinyanta Mwenya and the Zambian Community at Rhodes 
University for moral support 
 My fiancée Ms Chembo Mwape and my awesome friends; Ms Loisa Mbatha, Mr 
Gerald Machona, Ms Henusha Jhundoo, Ms Sonal Patel, Ms Tina Dreier, Mr Chiluba 
Mwila and Ms Rufaro Marowa. Chembo - Thank you for always having faith in me 
ii 
 
and bringing out the best that I never saw in myself. I would not have had any chance 
of succeeding at anything without your presence in my life. Loisa – Thank you for 
looking out for me and helping me to quickly adapt into a foreign place. You were 
always my perfect reminder of how it felt like to be home. Gerald – you are not just 
my friend, you are my brother. Thank you for being the one person I could totally 
relate to and for making me appreciate that we both share a common struggle. I wish 
you well in your endeavours. Henusha and Sonal – Thank you for sharing and 
allowing me to learn from your experiences and for teaching me how to be positive 
regardless of external circumstance. You are one of the most amazing people I have 
had a chance to know. Tina – You are a marvel to me. Your strength and resilience is 
inspiring. Thank you for showing me how to be strong and hard working. Chiluba – 
Just as the Beit Trust stated, you have been my “ready-made friend”. Thank you for 
always being there for me and for the moral support. Rufaro – Thank you for being 
my spiritual stamina and for encouraging me with so much positive energy. You have 
helped me become a conqueror in Christ. 
To my dad, thank you for reminding me that you are always there for me and for believing in 
me. To my brothers and sisters, every single time I worked hard in the lab, I did it for you. 
Thank you for showing me so much love. To the almighty God, Jesus the Christ, thank you 
for everything. 
 
 
 
 
 
 
 
 
 
iii 
 
Table of Contents 
Acknowledgements ..................................................................................................................... i 
Table of Contents ..................................................................................................................... iii 
List of Figures ........................................................................................................................ viii 
List of Schemes ......................................................................................................................... xi 
List of Tables ........................................................................................................................... xii 
List of Abbreviations ............................................................................................................. xiii 
Abstract .................................................................................................................................... xv 
Chapter 1 .................................................................................................................................. 1 
Literature Review .................................................................................................................... 1 
1.1 General Introduction to Diabetes Mellitus ................................................................. 1 
1.1.1 History of Diabetes .................................................................................................. 1 
1.1.2 Global Distribution .................................................................................................. 2 
1.2 Insulin............................................................................................................................. 4 
1.2.1 Biosynthesis of insulin............................................................................................. 4 
1.2.2 The insulin receptor ................................................................................................. 5 
1.3 Pathophysiology of diabetes mellitus type II .............................................................. 6 
1.3.1 Oxidative stress........................................................................................................ 7 
1.3.1.1 Natural defense system against oxidative stress .................................................. 7 
1.3.1.2 The role of oxidative stress in diabetes ................................................................ 8 
1.4 Presentation of diabetes mellitus ............................................................................... 10 
1.5 Diabetic complications ................................................................................................ 10 
1.5.1 Molecular mechanisms for the cause of diabetic complications ........................... 11 
1.5.2 Evaluation of the potential benefits of anti-oxidants ............................................. 11 
1.5.3 Diabetes as an inflammatory process .................................................................... 14 
1.6 Anti-diabetic therapeutic agents ................................................................................ 14 
1.6.1 Structural classification of current anti-diabetic drugs .......................................... 14 
iv 
 
1.6.1.1 Sulphonylureas ................................................................................................... 14 
1.6.1.2 Meglitinides ....................................................................................................... 16 
1.6.1.3 Biguanides.......................................................................................................... 17 
1.6.1.4 Gliptins (piperazine and cyanopyrrolidine derivatives) ..................................... 18 
1.6.1.5 Thiazolidinediones (TZDs) ................................................................................ 19 
1.6.1.6 α-glucosidase inhibitors (oligosaccharides and polyols) ................................... 20 
1.6.2 The search for new anti-diabetic lead compounds from natural sources .............. 21 
1.6.2.1 Terrestrial plant-derived potential anti-diabetic compounds ............................. 21 
1.6.2.2 Marine algae-derived potential anti-diabetic compounds .................................. 22 
1.7 Research objectives ..................................................................................................... 24 
References ............................................................................................................................... 25 
Chapter 2 ................................................................................................................................ 33 
In-vitro screening of selected South African marine algae ................................................. 33 
2.1 Introduction ................................................................................................................. 33 
2.1.1 Selection of South Africa endemic marine algae for screening ............................ 33 
2.2 Anti-oxidant/radical scavenging screening of crude algal extracts and fractions 36 
2.2.1 The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical assay .................................... 37 
2.3 Anti-inflammatory assay ............................................................................................ 38 
2.4 In-vitro cytotoxicity assays ......................................................................................... 38 
2.4.1 The Chang Liver cell line ...................................................................................... 39 
2.4.2 The HT-29 and Caco-2 cell lines ........................................................................... 39 
2.4.3 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay ..... 40 
2.5 Chapter aims ............................................................................................................... 40 
2.6 Results and Discussion ................................................................................................ 41 
2.6.1 Collection and extraction of South African algae ................................................. 41 
2.6.2 DPPH Anti-oxidant/radical scavenging activity of algal extracts ......................... 41 
2.6.3 Potential Anti-inflammatory activity of algal extracts .......................................... 42 
v 
 
2.6.4 Cytotoxicity profiles of the crude algal extracts .................................................... 44 
2.7 Experimental ............................................................................................................... 46 
2.7.1 General experimental ............................................................................................. 46 
2.7.2 Algal Material ........................................................................................................ 46 
2.7.3 Extraction of marine algae ..................................................................................... 46 
2.7.4 Sample preparation for in-vitro assays .................................................................. 47 
2.7.5 The DPPH Anti-oxidant assay ............................................................................... 47 
2.7.6 Anti-inflammatory assay ....................................................................................... 47 
2.7.7 In-vitro Cytotoxicity assays ................................................................................... 48 
References ............................................................................................................................... 49 
Chapter 3 ................................................................................................................................ 53 
Isolation and synthetic modification of prenylated toluhydroquinone and toluquinone 
metabolites from Sargassum heterophyllum ........................................................................ 53 
3.1 Introduction ................................................................................................................. 53 
3.1.1 Marine pharmacognosy of the Sargassum C. Agardh genus ................................. 53 
3.1.2 Previously isolated compounds from Sargassum species ..................................... 54 
3.1.3 Bioactive compounds isolated from S. heterophyllum .......................................... 55 
3.1.4 Chapter aims .......................................................................................................... 55 
3.2 Results and Discussion ................................................................................................ 56 
3.2.1 Extraction and isolation of metabolites from Sargassum heterophyllum .............. 56 
3.2.2 Structural characterization of isolated compounds ................................................ 59 
3.2.2.1 Characterization of compound 3.6 ..................................................................... 59 
3.2.2.2 Characterization of compound 3.7 ..................................................................... 61 
3.2.2.3 Characterization of compound 3.8 ..................................................................... 64 
3.2.3 Synthesis of sargahydroquinoic acid derivatives ................................................... 66 
3.3 Experimental ............................................................................................................... 72 
3.3.1 General experimental procedures .......................................................................... 72 
vi 
 
3.3.2 Algal Material ........................................................................................................ 72 
3.3.3 Extraction and Isolation of metabolites ................................................................. 72 
3.3.4 Semi-synthesis of derivatives ................................................................................ 74 
3.3.4.1 Oxidation of sargahydroquinonic acid (3.6) to sargaquinoic acid (3.1) ............ 74 
3.3.4.2 Conversion of sargaquinoic acid (3.1) to sargachromenoic acid (3.9) .............. 74 
3.3.4.3 Conversion of sargahydroquinoic (3.6) acid to sarganaphthoquinone (3.10) .... 74 
References ............................................................................................................................... 76 
Chapter 4 ................................................................................................................................ 79 
In-vitro anti-diabetic (insulinomimetic) activity of sargahydroquinoic acid semi-
synthetic derivatives............................................................................................................... 79 
4.1 Introduction ................................................................................................................. 79 
4.1.1 Mechanistic selection of an in-vitro anti-diabetic model ...................................... 79 
4.1.1.1 Adipocytes as an insulin target tissue ................................................................ 80 
4.1.1.2 Sargahydroquinoic acid and sargaquinoic acid as potential PPARα/γ agonists 81 
4.1.1.3 The 3T3-L1 preadipocyte differentiation ........................................................... 82 
4.1.2 Chapter aims .......................................................................................................... 84 
4.2 Results and Discussion ................................................................................................ 85 
4.2.1 DPPH anti-oxidant/radical scavenging Assays ..................................................... 85 
4.2.2 Potential anti-inflammatory activity of S. heterophyllum fractions ...................... 88 
4.2.3 Cytotoxicity assays for crude extracts and pure compounds ................................. 90 
4.2.4 3T3-L1 preadipocyte differentiation assay ............................................................ 93 
4.3 Experimental ............................................................................................................... 96 
4.3.1 General experimental procedures .......................................................................... 96 
4.3.2 DPPH radical scavenging assay ............................................................................ 96 
4.3.3 Anti-inflammatory assays ...................................................................................... 96 
4.3.4 Cytotoxicity assays ................................................................................................ 96 
4.3.5 3T3-L1 preadipocyte differentiation assay ............................................................ 97 
vii 
 
References ............................................................................................................................... 98 
Chapter 5 .............................................................................................................................. 101 
Conclusion ............................................................................................................................ 101 
Appendix I ............................................................................................................................. 103 
Appendix II ............................................................................................................................ 106 
Appendix III ........................................................................................................................... 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
List of Figures 
Figure 1.1 Comparative prevalence (%) of diabetes (20-79 years)..........................................................2 
Figure 1.2 Comparative prevalence (%) of diabetes (20-79 years) by IDF region...................................3 
Figure 1.3 The insulin signalling pathway...............................................................................................6 
Figure 1.4 Generation of free radicals and the natural anti-oxidant defense mechanism………………..8 
Figure 1.5 Metal catalyzed auto-oxidation of glucose……………………………………………………..9 
Figure 1.6 Structures of IPTD and Carbutamide.....................................................................................14 
Figure 1.7 The general structure of sulphonylureas................................................................................15 
Figure 1.8 Selected structures of first, second and third generation sulphonylureas...............................15 
Figure 1.9 Structure derivatization of meglitinides…………………………………………………………...17 
Figure 1.10 Structures of biguanides………………………………………………………………………….18 
Figure 1.11 Structures of sitagliptin (1.12) and vildagliptin (1.13)...................................................................18 
Figure 1.12 Selected structures of thiazolidinediones (TZDs)..........................................................................19 
Figure 1.13 Structures of α-glucosidase inhibitors..................................................................................20 
Figure 1.14 Selected structures of plant-derived potential anti-diabetic compounds…………………………22 
Figure 1.15 Selected structures of marine-derived potential anti-diabetic compounds……………………….23 
Figure 2.1 Images of S. zonale (a), D. ligulata (b), C. fibrosa (c), B. capensis (d), Sargassum sp. (e) and S. 
heterophyllum.....................................................................................................................................................35 
Figure 2.2 A selection of anti-oxidant compounds isolated from various algal species...................................36 
Figure 2.3 Anti-oxidant mediated conversion of diphenylpicrylhydrazyl (2.12) (purple) to diphenylpicryl-
hydrazine (2.13) (yellow)...................................................................................................................................37 
Figure 2.4 The structure of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, 2.14).....40 
Figure 2.5 Nitrate production and cell viability in murine macrophages (RAW264.7) treated with S. zonale (8a), 
D. ligulata (8b), C. fibrosa (8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude 
extracts................................................................................................................................................................43 
Figure 3.1 Prenylated compounds isolated from the Sargassum genera possessing various biological 
activities................................................................................................................... ...........................................55 
ix 
 
Figure 3.2 
1
H NMR spectrum (CDCl3, 400MHz) of S. heterophyllum crude extract………………………..56 
Figure 3.3 
1
H NMR spectra (CDCl3, 400 MHz) of S. heterophyllum silica gel column fractions 64a-i…….58 
Figure 3.4 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.6...............................................................59 
Figure 3.5 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.6..............................................................60 
Figure 3.6 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.7...............................................................61 
Figure 3.7 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.7..............................................................62 
Figure 3.8 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.8...............................................................64 
Figure 3.9 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.8..............................................................65 
Figure 3.10 
1
H NMR spectra (CDCl3, 400 MHz) of compounds 3.1, 3.6, 3.9 and 3.10..................................67 
Figure 4.1 Schematic overview of the sequential steps involved in the 3T3-L1 differentiation process........ 83 
Figure 4.2 Titration curves for DPPH anti-oxidant activity of fractions (64c), (64d) and (64c).....................85 
Figure 4.3 Titration curves for DPPH radical scavenging activity of sargahydroquinoic acid (3.6) and 
sargachromenoic acid (3.9)............................................................................................................................. ..86 
Figure 4.4 Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions 
(64c), (64d), (64e) and (64f)............................................................................................... ..............................89 
Figure 4.5 Dose dependent inhibition of proliferating 3T3-L1 cell viability by sargahydroquinoic acid (3.6), 
sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10).............................92 
Figure 4.6 Dose dependent lipid accumulation in differentiating 3T3-L1 cells after treatment with 
sargahydroquinoic acid (3.6), sargaquinoic acid (3.1), sargachromenoic acid (3.9), sarganaphthoquinoic acid 
(3.10) and positive controls rosiglitazone and troglitazone..............................................................................94 
Figure 4.7 Representative images of oil Red O stained 3T3-L1 cells after treatment with sargahydroquinoic  
acid (3.6), sargaquinoic acid (3.1), sargachromenoic acid (3.9), sarganaphthoquinoic acid (3.10) and 
rosiglitazone......................................................................................................................................................95 
Figure A1.1 Titration curves for DPPH radical scavenging activity of the crude extracts S. zonale (8a), D. 
ligulata (8b), C. fibrosa (8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62)…………....103 
Figure A1.2 Titration curves for the DPPH radical scavenging activity of Sargassum heterophyllum crude 
fractions (64a), (64b), (64c), (64d), (64e) and (64g).................................................................................. ....104 
Figure A1.3 Titration curves for DPPH radical scavenging activity of sarganaphthoquinoic acid (3.10), 
sargahydroquinoic acid (3.6), sargaquinoic acid (3.1) and sargachromenoic acid (3.9)................................105 
x 
 
Figure A2.1a Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions 
(64a), (64b), (64c) and (64d)..........................................................................................................................106 
Figure A2.1b Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions 
(64e), (64f), (64g) and (64i)............................................................................................................................107 
Figure A3.1 Dose dependent inhibition of Chang liver cell viability by S. zonale (8a), D. ligulata (8b), C. 
fibrosa (8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts……………....108 
Figure A3.2 Dose dependent inhibition of HT-29 cell viability by S. zonale  (8a), D. ligulata (8b), C. fibrosa 
(8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts…………....................109 
Figure A3.3 Dose dependent inhibition of Caco-2 cell viability by S. zonale (8a), D. ligulata (8b), C. fibrosa 
(8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts…………....................110 
Figure A3.4 Dose dependent inhibition of Chang liver cell viability by S. heterophyllum fractions (64a), (64b), 
(64c), (64d), (64e), (64f), (64g), (64h) and (64i).............................................................................................111 
Figure A3.5 Dose dependent inhibition of HT-29 cell viability by S. heterophyllum fractions (64a), (64b), 
(64c), (64d), (64e), (64f), (64g), (64h) and (64i).............................................................................................112 
Figure A3.6 Dose dependent inhibition of Caco-2 cell viability by S. heterophyllum fractions (64a), (64b), 
(64c), (64d), (64e), (64f), (64g), (64h) and (64i).............................................................................................113 
Figure A3.7 Dose dependent inhibition of Chang liver cell viability by sarganaphthoquinoic acid (3.10), 
sargahydroquinoic acid (3.6), sargaquinoic acid (3.1) and sargachromenoic acid (3.9).................................114 
 
 
 
 
 
 
 
 
 
xi 
 
List of Schemes 
Scheme 1.1 Reaction schemes for the anti-oxidant and pro-oxidant activity of α-tocopherol.......................11 
Scheme 3.1 Isolation of compounds 3.6, 3.7, and 3.8 from S. heterophyllum...............................................57 
Scheme 3.2 Synthesis of sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid 
(3.10)............................................................................................................................. ..................................66 
Scheme 3.3 Proposed mechanism for the synthetic conversion of sargaquinoic acid (3.1) to              
sargachromenoic acid (3.9)............................................................................................................................. 68 
Scheme 3.4 Proposed biosynthetic pathway for sarganaphthoquinoic acid (4.2) from sargahydroquinoic        
acid (3.6). (a) Oxidation, (b) Friedel-Craft’s alkylation.................................................................................69 
Scheme 3.5 Proposed mechanism for the synthetic conversion of sargahydroquinoic acid (3.6) to 
sarganaphthoquinoic acid (3.10).....................................................................................................................70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Tables 
Table 2.1 IC50 values for the DPPH radical scavenging activity of S. zonale (8a), D. ligulata (8b),                    
C. fibrosa (8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts…………..42 
Table 2.2 EC50 values for S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. capensis (8d), Sargassum sp.    
(8e) and S. heterophyllum (62) crude extracts against Chang liver, HT-29 and Caco-2 cells.......................44 
Table 3.1 
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data for compounds 3.6       
and 3.7............................................................................................................................. ...............................63 
Table 3.2 
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data for compound 
3.8............................................................................................................................. ......................................65 
Table 3.3 
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data for compounds 3.1       
and 3.9............................................................................................................................. ...............................71 
Table 4.1 IC50 values for the DPPH radical scavenging activity of S. heterophyllum fractions...................85 
Table 4.2 IC50 values for the DPPH radical scavenging activity of sargahydroquinoic acid (3.6),       
sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10)..........................86 
Table 4.3 EC50 values for S. heterophyllum fractions against Chang Liver, HT-29 and Caco-2 cells.........90 
Table 4.4 Cytotoxicity IC50 values for sargahydroquinoic acid (3.6), sargaquinoic acid (3.1),      
sargachromenoic acid (3.9) and sarganaphthoquinone (3.10) against Chang Liver and 3T3-L1 cell lines..91 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Abbreviations 
 
µM   Micromolar 
µmol   Micromoles 
Ag2O   Silver oxide 
CDCl3   Deuterated chloroform 
CH2Cl2  Dichloromethane 
CHCl3   Trichloromethane/ chloroform 
d   Doublet 
dd   Doublet doublet 
DM   Diabetes mellitus 
DMEM  Dulbecco’s Modified Eagles Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DPPH   2,2-diphenyl-1-picrylhydrazyl radical 
EC50   50% Effective Concentration 
EtOAc   Ethyl acetate 
EtOH   Ethanol 
FBS   Fetal Bovine Serum 
FCS   Fetal Calf Serum 
Fr   Fraction 
GDM   Gestational diabetes mellitus 
HOPE   Heart Outcomes Prevention Evaluation Study 
HPLC   High Performance Liquid Chromatography 
Hz   Hertz 
IC50   50% Inhibitory Concentration 
IDDM   Insulin dependent diabetes mellitus 
xiv 
 
IDF   International Diabetes Federation 
J   Spin-spin Coupling Constant 
m   Multiplet 
MeOH   Methanol 
MHz   Megahertz 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
Mult   Multiplicity 
NDK   Noordhoek 
NIDDM  Non-Insulin dependent diabetes mellitus 
NMR   Nuclear Magnetic Resonance spectroscopy 
ºC   Degrees Celsius 
PPARγ  Peroxisome proliferator-activated receptor gamma 
ppm   Parts per million 
PTP1B   Protein tyrosine phosphatase 1B 
q   Quartet 
s   singlet 
SHQA   Sargahydroquinoic acid 
SQA   Sargaquinoic acid 
STZ   Streptozotocin 
TZD   Thiazolidinediones 
WHO   World Health Organization 
δ   Chemical shift (ppm) 
 
 
 
 
xv 
 
Abstract 
 
In Africa, non-communicable diseases such as diabetes mellitus have been generally 
neglected. This problem has worsened over the years owing to continuous threats from 
infectious diseases such as HIV/AIDS, tuberculosis and malaria. Despite this, statistics have 
shown that by 2030, the African region will have the highest proportional increase in diabetes 
prevalence. Over 80% of all diabetic deaths occur in developing countries probably not only 
due to poor equity of access to medication but also due to limited efficacy and side effects 
associated with the commonly available anti-diabetic agents. Therefore, this creates the 
desperate need for the development of new anti-diabetic agents that are more efficacious and 
can be sourced from within the continent. 
With oxidative stress as a suggested mechanism underlying the cause of diabetes mellitus and 
diabetic complications, the discovery of natural anti-oxidants that prevent free radical 
mediated damage is important for developing new treatment strategies. Marine algae have 
been identified as good sources for natural anti-oxidants. Unfortunately, very few studies 
have embarked on the discovery of marine-derived anti-oxidant compounds with potential 
anti-diabetic activity. 
In this project, we investigated the potential anti-oxidant activity of the South African 
endemic algae Stypopodium multipartitum, Dictyopterus ligulata, Cystophora fibriosa, 
Bifurcariopsis capensis, Sargassum sp. and Sargassum heterophyllum. From these studies, 
Sargassum heterophyllum yielded prenylated compounds, the main compound being 
sargahydroquinoic acid (3.6) and the carotenoid metabolite fucoxanthin (3.8), which are in 
part responsible for the radical scavenging activity of the crude extract. Sargahydroquinoic 
acid (3.6) and fucoxanthin (3.8) also exhibited significant anti-inflammatory activity. 
Sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10) 
were then semi-synthesized from sargahydroquinoic acid (3.6) and their in-vitro cytotoxicity 
profiles evaluated using Chang Liver, HT-29, Caco-2 and 3T3-L1 cell lines prior to anti-
diabetic testing. From the semi-synthetic derivatives, sargachromenoic acid (3.9) exhibited 
the most potent anti-oxidant activity (IC50 = 6.99 µg/mL). After the evaluation of anti-
diabetic activity using 3T3-L1 preadipocyte differentiation, sarganaphthoquinoic acid (3.10) 
showed the most potent insulinomimetic activity at 1.19 µM by inducing a PPARγ response 
similar to that of rosiglitazone at 1 µM. 
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Chapter 1 
Literature Review 
1.1 General Introduction to Diabetes Mellitus 
Diabetes mellitus (DM) is a heterogeneous disease which is mainly comprised of poor insulin 
secretion and lack of insulin sensitivity (Puavilai et al. 1999). Regardless of aetiological 
cause, diabetes is associated with hyperglycaemia (American Diabetes Association 2009), 
which is defined as a sustained elevation of glucose in blood plasma. In 1979, The National 
Diabetes Data Group (NDDG) and the World Health Organisation (WHO) classified diabetes 
mellitus as Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent 
Diabetes Mellitus (NIDDM) (Alberti and Zimmet 1998). However, due to complications in 
epidemiologic evaluation and clinical management as well as the discovery of other types of 
diabetes with different pathophysiologies, a new classification was implemented comprising 
of four major classifications which are: Diabetes mellitus type I (formally called IDDM), 
diabetes mellitus type II (formally called NIDDM), Gestational Diabetes Mellitus (GDM) and 
diabetes secondary to other conditions such as endocrinopathies, drug/chemical-induced, 
infections and genetic syndromes (Mayfield 1998). The global diabetes morbidity sums up to 
346 million people, with a 90% contribution from type II diabetics (WHO 2012). More than 
80 % of diabetes associated deaths occur in low to middle income countries with the 
mortality rate estimated to double between 2005 and 2030 (WHO 2012). These findings 
therefore disprove the common belief that diabetes is a disease for the ‘rich man’. 
1.1.1  History of Diabetes 
The term ‘diabetes’ is derived from a greek word ‘diabainein’ (διαβητησ), which means ‘to 
pass through’ or ‘to siphon’ (Adeghate 2001). The naming of diabetes was due to the 
classical symptoms of excessive thirst (polydipsia) and frequent urination (polyuria) 
associated with the disease. An ancient Egyptian medical manuscript discovered by German 
Egyptologist Georg Ebers (1550 B.C.) known as The Ebers Papyrus was the first 
documentation to mention the polyuric state of the disease which was later clearly described 
as diabetes mellitus type I by Aretaeus of Cappadocia in 2
nd
 Century A.D (Tattersall 2010). 
Between the 5
th
 and 6
th
 Century A.D., two Hindu physicians, Charak and Shushrut, were the 
first to recognize the sweetness of diabetic urine which they referred to as ‘Madhumeha’ 
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meaning ‘passing large volumes of sweet urine’ (Ramachandran and Snehalatha 2009). They 
achieved this diagnosis by tasting the urine or noticing the congregation of ants around it, 
with the latter being the commonest African traditional way of diagnosing diabetes today 
(Tattersall 2010). In 1776, a physician to the Liverpool infirmary, Matthew Dobson, was the 
first to describe hyperglycaemia by showing that the sweetness of diabetic urine was as a 
result of glucose which preceded and accompanied the glucose in blood (Lock and Bonventre 
2008). He further evaporated the urine of his 33 year old patient, Peter Dickonson, to a ‘white 
cake’ with a smell and taste that was indistinguishable from sugar (Tattersall 2010). An 
Edinburgh-trained surgeon John Rollo became the first to coin the term ‘mellitus’ to diabetes 
from the Latin word meaning ‘honey’(Skljarevski 2007). 
1.1.2 Global Distribution 
Diabetes is a disease that affects all ages and races. The disease has created a significant 
heath problem and is an economical burden to many people (Narayan et al. 2006). Diabetes 
has now been considered as a major health threat in the 21
st
 Century (Zimmet 2001). In a 
report compiled by the International Diabetes Federation (IDF), it has been realised that since 
the current diabetes morbidity (366 million) is expected to exceed half a billion by the year 
2030, the epidemic trajectory of diabetes has become similar to that of climate change and 
hence, concerted efforts are desperately required to curb the disease (IDF 2012). 
 
Figure 1.1 Comparative prevalence (%) of diabetes (20-79 years) (International Diabetes 
Federation 2011) 
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According to Wild et al., these figures underestimate future diabetes`` prevalence since 
demographic studies show an increase in the ‘diabetic epidemic’ even if the levels of obesity 
remain constant (Wild et al. 2004). It is pertinent to note that even though the prevalence of 
diabetes in Africa is comparatively less than those from other IDF regions (Figure 1.2), 
statistics estimate that the African region will experience a 98.1 % proportional increase in 
diabetes cases by 2030 (Shaw et al. 2010). 
 
Figure 1.2 Comparative prevalence (%) of diabetes (20-79 years) by IDF region 
(International Diabetes Federation 2011)
1
 
 
 
 
 
 
 
 
 
                                                          
1
 Seven IDF regions were approved by the General Council in 1982 based on the regional structure of the World 
Health Organisation (WHO) for the strengthening of diabetes association’s worldwide. These are; Africa (AFR), 
Europe (EUR), Middle East and North Africa (MENA), North America and Caribbean (NAC), South and 
Central America (SACA), South-East Asia (SEA) and Western Pacific (WP). 
4 
 
1.2 Insulin 
Discovered in 1922 by Sir Frederick Grant Banting and Dr. Charles Best, Insulin is a crucial 
regulator of metabolic physiology (Myers and White 1996). Pessin and Saltiel described 
insulin as “the most potent anabolic hormone known which is also essential for appropriate 
tissue development, growth and maintenance of whole-body glucose homeostasis” (Pessin 
and Saltiel 2000). Diabetes mellitus is a disease caused by either lack of insulin (diabetes 
mellitus type I) or the inability to adequately compensate for a reduced insulin response 
(diabetes mellitus type II) (Myers and White 1996). 
1.2.1 Biosynthesis of insulin 
The islets of Langerhans are described as an endocrine organ occupying about 1% of the 
pancreas characterized by the presence of a central core made up of pancreatic β-cells (Weir 
and Bonner-Weir 1990) which are unique cells that not only produce but also control the 
release of insulin to ensure that blood glucose levels are maintained (Lipson et al. 2006). 
Specialization of pancreatic β-cells for the production and storage of insulin is evidenced by 
the fact that insulin comprises approximately 10% (10 pg/cell) of the total β-cell protein 
(Jones and Persaud 2010). Insulin consists of two polypeptide chains (A and B) which are 
linked by disulphide bonds. It is synthesized as a single polypeptide chain called 
preproinsulin (Chan et al. 1976;Harper et al. 1981). The gene that codes for preproinsulin is 
1355 base pairs in length with a coding region consisting of three exons: the first encoding 
the signal peptide at the N-terminus of preproinsulin, the second encoding the B chain and 
part of the C (connecting) peptide, and the third encoding the rest of the C peptide and the A 
chain (Jones and Persaud 2010). Rapid, mainly co-translational, cleavage of preproinsulin to 
proinsulin takes place in the rough endoplasmic reticulum. The proinsulin  is then transported 
into the Golgi apparatus to be stored in granular form (Steiner et al. 1985). Through the 
sequential action of two endopeptidases (prohormone convertases 2 and 3) and 
carboxypeptidase H, the C peptide chain is removed to liberate two cleavage dipeptides 
which finally yields insulin (Hutton 1994). Insulin is concurrently stored with C peptide in 
secretory granules to be released in equimolar quantities by regulated exocytosis normally 
with >95% of the secretory product as insulin (with C peptide) and <5% as proinsulin (Jones 
and Persaud 2010). 
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1.2.2 The insulin receptor 
Since the discovery of insulin the most fundamental problem to diabetes research has been 
that of understanding how insulin works at the cellular level (Sun et al. 1991). The insulin 
receptor (IR) is a member of a subfamily of receptor tyrosine kinases. Other receptors that 
belong to this subfamily are the insulin-like growth factor (IGF)-I receptor and the insulin 
receptor-related receptor (IRR). These receptors are tetrameric proteins characterized by the 
presence of four glycoprotein subunits (two α and two β) with allosteric enzyme properties 
(Saltiel and Kahn 2001). The subunits are synthesized on a single mRNA, proteolytically 
separated and then bound to each other by disulfide bonds to form the insulin receptor with a 
molecular weight of approximately 340,000 (Ganong 2003). When insulin binds to the α 
subunit of the insulin receptor, the receptor undergoes conformational changes which trigger 
the activation of intrinsic tyrosine kinase activity in the β subunit (Liu et al. 2010). This 
results in the phosphorylation of insulin receptor substrate proteins (IRS) such as IRS-1 (the 
prototype for this type of molecule) IRS-2, IRS-3, Gab-1 and p62
dok
 functioning as insulin 
receptor-specific docking proteins to engage multiple downstream signaling molecules 
(White 1998). The phosphorylated IRS activates two distinct insulin signaling pathways: 
protein kinase B/glycogen synthase kinase 3β (Akt/GSK3β)2 and ras-extracellular signal-
related kinases (ras-ERK)
3
 (Liu et al. 2010). Phosphorylated IRS-1 activates phosphoinositol 
3 kinase (PI3K), which subsequently activates Akt2 and GSK and thereby inhibits GSK 
mediated phosphorylation of glycogen synthesis. This results in the regulation of glycogen 
and lipid synthesis as well as stimulation of glucose uptake (Figure 1.3) (Liu et al. 2010).  
                                                          
2
 Akt, also known as protein kinase B, is a serine/threonine protein kinase with multiple cellular functions 
including glucose metabolism, apoptosis and cell migration. Of the 3 genes encoding the Akt family in humans 
(Akt1, Akt2 and Akt3), Akt2 is important in insulin signalling for the induction of glucose transport. GSK-3 is a 
serine/threonine protein kinase that mediates the addition of phosphates onto serine and threonine amino acid 
residues. It is encoded by two genes; GSK-3α and GSK-3β which play a role in type II diabetes mellitus. 
3
 Ras is a prototype member of the Ras superfamily of small GTPase proteins. Activated Ras plays a role in cell 
growth, differentiation and survival. Ras is activated by guanine nucleotide exchange factors encoded by a set of 
genes called the Son of Sevenless (SOS). ERK, also known as MAPK1 and MAPK3, are serine/threonine 
kinases (Bivona and Philips 2003). 
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Figure 1.3 The insulin signalling pathway (Liu et al. 2010) 
1.3 Pathophysiology of diabetes mellitus type II 
Although the etiological cause of diabetes is still undefined, viral infection, autoimmune 
disease and environmental factors have been implicated (Maritim et al. 2003). The 
pathogenesis of diabetes mellitus type II is very complicated and usually involves defective 
β-pancreatic cells and diminished insulin sensitivity. This causes increased rates of hepatic 
and renal glucose output as well as decreased glucose clearance from the circulation (Kahn 
2001). The presence of hyperglycaemia in type II diabetes is normally accompanied by β-cell 
dysfunction which manifests in several ways such as hypo-insulinaemia, alterations in insulin 
secretion, an anomaly in the conversion of proinsulin to insulin and decreased release of 
amylin (Kahn 2001). Even though the presence of defective β-cells is evident in all 
hyperglycemic patients, the onset of this abnormality and the responsible factors which 
contribute to this change are still debatable subjects (Kahn 2001). While some suggested that 
insulin resistance is the primary defect and that β-cell dysfunction comes later due to insulin 
resistance associated secretory demand (DeFronzo and Ferrannini 1991), data from The 
United Kingdom Prospective Diabetes Study (UKPDS) suggests that the onset of β-cell 
dysfunction occurs prior to the development of hyperglycemia and may commence many 
years before the diagnosis of diabetes (Kahn 2003). 
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1.3.1 Oxidative stress 
Oxidative stress has been defined as “the excessive formation and/ or the insufficient removal 
of highly reactive molecules such as reactive oxygen species (ROS) and reactive nitrogen 
species (RNS)” (Johansen et al. 2005). These ROS and RNS can be divided into free radical 
and non radical species. Examples of biologically relevant ROS free radical species are 
superoxide (•O2
-), hydroxyl (•OH), peroxyl (•RO2) and hydroperoxyl (•HRO2
-
). Examples of 
ROS non radical species are hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) 
(Evans et al. 2002). Examples of RNS free radical species are nitric oxide (•NO) and nitrogen 
dioxide (•NO2
-
). Examples of RNS non radical species are peroxynitrite (ONOO
-
) and nitrous 
oxide (HNO2) (Evans et al. 2002). Due to their cardinal role in the pathophysiology of 
diabetes, superoxide, nitric oxide and peroxynitrite have been the focus of several studies 
(Johansen et al. 2005). 
1.3.1.1 Natural defense system against oxidative stress 
Molecular oxygen (O2) is a terminal electron acceptor in aerobic life which is regarded as a 
bi-radical because of its possession of two unpaired electrons of parallel spin (Blake et al. 
1987). Through enzymatic, non-enzymatic and mitochondrial pathways (Figure 1.4), 
molecular oxygen undergoes univalent reduction to form superoxide (•O2
-
) (Johansen et al. 
2005). For instance, when phagocytes are exposed to a certain stimuli their rate of oxygen 
uptake increases and results in an increased production of superoxide and hydrogen peroxide 
often referred to as the “respiratory burst” (Babior 1984).  From in vitro observations, the 
mitochondrion may be one of the major intracellular sources of reactive oxygen species with 
ubisemiquinone and ubiquinol as the main sources of mitochondria generated superoxide 
(Blake et al. 1987). Because of its electronic configuration, superoxide can act as a reducing 
agent, an oxidizing agent and a nucleophile. Therefore, to prevent cellular auto-oxidative 
damage as a consequence of free radicals generated during normal metabolism, superoxide is 
spontaneously dismutated to hydrogen peroxide through catalytic breakdown by the enzymes 
manganese superoxide dismutase (MnSOD) and copper superoxide dismutase (CuSOD) 
depending on whether the superoxide is mitochondrial or cytosolic respectively (Figure 1.4) 
(Blake et al. 1987). 
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Figure 1.4 Generation of free radicals and the natural anti-oxidant defense mechanism 
(Johansen et al. 2005). 
Hydrogen peroxide is then detoxified by either glutathione peroxidase (GSH-Px) in the 
mitochondria or catalase (CAT) in the peroxisomes to form water and oxygen. The enzyme 
glutathione reductase (GSH-reductase) generates glutathione (GSH) from glutathione 
disulfide (GSSG) (Johansen et al. 2005). Glutathione is both a radical scavenger and a co-
substrate for glutathione peroxidase by acting as a hydrogen donor in the elimination of water 
and oxygen from hydrogen peroxide (Figure 1.4) (Johansen et al. 2005). Excessive formation 
of free radicals exhausts this defense mechanism causing •O2
-
 to react with endothelial •NO 
leading to the formation of highly reactive peroxynitrite (ONOO
-
). Similarly, transition 
metals catalyze the conversion of excess H2O2 into •OH radicals through the Fenton reaction 
(Evans et al. 2002). 
1.3.1.2 The role of oxidative stress in diabetes 
We have already established that the pathogenesis of diabetes mellitus type II mostly requires 
defects in both β-pancreatic cells and insulin sensitivity (Kahn 2001). Although the levels of 
intrinsic anti-oxidant enzymes (MnSOD, CuSOD, GSH-Px and CAT) in β-pancreatic cells 
are reasonable, the total anti-oxidant enzyme activity may be low thereby making them more 
susceptible to oxidative damage (Oberley 1988). Studies involving the induction of diabetes 
in animals using alloxan and streptozotocin (STZ) has increased understanding of the role 
played by oxidative damage in the cause of diabetes (Wolff 1993). Alloxan (2,4,5,6-
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tetraoxohexahydropyrimidine) is converted to dialuric acid, which then undergoes auto-
oxidization to yield H2O2, O2, •O2
-
 and •OH free radicals (Oberley 1988). The cytotoxic 
effects of alloxan on β-pancreatic cells is attributed to the efficiency with which the drug is 
absorbed by the cells, the extent to which the drug interacts with intracellular reducing agents 
to produce oxidants and decreased amounts of glutathione peroxidase in the islets (Wolff 
1993). Despite the mechanism of action of STZ being unknown, inhibition of STZ-induced 
diabetes by desferrioxamine indicates that STZ toxicity may be a result of free radical 
reactions catalyzed by transition-metals. According to Wolf (1993), the aetiological cause of 
diabetes mellitus may at least be a product of oxidative stress resulting from transition metal 
catalysis and thus, individual variations in the levels of transition metals might determine 
susceptibility to diabetic complications. During diabetes or insulin resistance, failure of 
insulin-stimulated glucose uptake by fat and muscle causes a sustained elevation of glucose 
concentrations in blood plasma. Consequently, this ensuing hyperglycaemia causes an 
increase in the glucose uptake of insulin-independent tissues leading to the enhancement of 
oxidant production and impairment of anti-oxidant defenses by multiple interacting pathways 
(King and Loeken 2004). In the hyperglycaemic state, glucose undergoes monosaccharide 
auto-oxidation by enolizing to form enediol products which, in the presence of transitional 
metals produce enediol radical anions (Figure 1.5). These enediol radical anions react with 
molecular oxygen under physiological conditions to give off dicarbonyl products, superoxide 
radicals and hydrogen peroxide which, in the presence of transitional metals, further produces 
hydroxyl radicals. These generated free radicals ultimately result in oxidative stress. Studies 
have shown that oxidative stress due to hyperglycaemia plays a crucial role in the 
pathogenesis of diabetic complications (Evans et al. 2002). 
 
Figure 1.5 Metal catalyzed auto-oxidation of glucose (Bierhaus et al. 1998) 
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1.4 Presentation of diabetes mellitus 
The main feature of patients with diabetes mellitus (DM) type II is the presence of sustained 
elevation of serum glucose levels while that of DM type I patients is the occurrence of 
metabolic decompensations such as diabetic ketoacidosis (Pinhas-Hamiel and Zeitler 2007). 
Increased thirst (polydipsia) and increased urinary volume (polyuria), frequency of low 
immunity associated infections and about 25% of girls with type II DM have a vaginal 
monilial infection as their chief complaint at presentation which is exceedingly rare in DM 
type I but a typical complaint among adult females with DM type II as an indicator of long 
standing glycosuria. The remaining DM type II patients are subjected to infectious diseases 
mainly of the bones and the pharynx, excessive weight gain, painful urination and urinary 
incontinence (Pinhas-Hamiel and Zeitler 2007). 
1.5 Diabetic complications 
Diabetic complications can be classified into short term and long term effects. The short term 
effects of diabetes include keto-acidosis, recurrent infections and weight loss. The long term 
effects of diabetes are generally classified into micro-vascular and macro-vascular 
complications (Nazimek-Siewniak et al. 2002). The micro-vascular complications include 
retinopathy, nephropathy and neuropathy (Donaghue et al. 2009) while the macro-vascular 
complications include cardiovascular diseases such as heart failure, coronary heart disease, 
stroke, peripheral vascular disease and myocardial infarction (Rosenson et al. 2011). Some of 
the outcomes of micro-vascular complications include visual disturbances and loss of sight, 
renal and cardiovascular complications, abnormal sensations, myasthenia and peripheral 
nervous system disorders (Donaghue et al. 2009). Cardiovascular complications are the 
leading cause of morbidity and mortality in diabetic patients (Adeghate 2004). About 50% of 
all diabetic patients die of cardiovascular disease (WHO 2012) with 75% of all deaths caused 
by myocardial infarction and stroke (Ban et al. 2009). Compared with non-diabetics, diabetic 
patients have a several-fold increased risk of developing cardiovascular disease comprised of 
a 10 times higher risk and a 3 times higher risk for type I and type II diabetics respectively 
(Ban et al. 2009). 
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1.5.1 Molecular mechanisms for the cause of diabetic complications 
The role of hyperglycaemia in the development of diabetic complications is mainly through 
the induction of oxidative stress arising from hyperglycaemia associated production and 
release of ROS and RNS which ultimately leads to abnormal gene expression, faulty signal 
transduction and apoptosis (via activation of p53 and the cytochrome c-activated caspase 3 
pathway) (Adeghate 2004). The four major hypotheses that explain how hyperglycaemia 
causes diabetic complications are: increased conversion of glucose to sorbitol which 
ultimately results in the failure to regenerate the reduced form of glutathione, reactions 
between the products of glucose auto-oxidation and amino acid groups to form advanced 
glycation end-products (AGE), polyacylglycerol (PAG) mediated activation of protein 
kinases and alterations in genes and protein function due to hexosamine pathway activation 
(Brownlee 2001). It was discovered that all these different pathogenic mechanisms reflect a 
single hyperglycaemia-induced unifying hypothesis which is the overproduction of super 
oxide (•O2
-
) by the mitochondrial electron transport chain (Brownlee 2005). Diabetic 
complications are a result of lipid peroxidation, protein nitration and DNA damage caused by 
peroxynitrite (ONOO
-
), a highly reactive free radical product formed when overproduced 
•O2
-
 reacts with •NO (Johansen et al. 2005) at a rate constant of 6.7 × 109 M−1s−1 (Aruoma 
1998). 
1.5.2 Evaluation of the potential benefits of anti-oxidants 
Having explained the involvement of hyperglycaemia-induced oxidative stress in the 
development of diabetic complications, the theoretical implication is that hypoglycaemic 
agents with additional anti-oxidant activity should render a long term advantage in avoiding 
diabetic complications over those which are only focused on the meticulous control of 
hyperglycaemia. However, the use of anti-oxidants in the management of type II diabetes has 
been met with huge challenges. For instance, the use of the anti-oxidant α-tocopherol 
(Vitamin E) as an adjunct to conventional anti-diabetic therapy in clinical trials for the 
prevention of cardiovascular events has produced conflicting results. The most significant 
results came from the HOPE and HOPE TOO trials in which supplementation with Vitamin E 
in patients with vascular disease or diabetes increased the risk of developing heart failure 
(RR= 1.13) (Lonn et al. 2005). Under high oxidative stress conditions, the main mechanism 
for the anti-oxidant activity of α-tocopherol involves the direct inactivation of one free radical 
(R
•) by one molecule of α-tocopherol (TocH) (Scheme1.1, Reaction 1) followed by the 
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scavenging of a second radical by the formed α-tocopheroxyl radical (Toc•) (Scheme 4.1, 
Reaction 2) ultimately resulting in the neutralization of two free radicals with one molecule 
of α-tocopherol (Kontush et al. 1996). 
TocH + R• RH + Toc• Reaction 1
Toc• + R• Non Radical Products
Toc• + LH TocH + L•
Cu2+ + TocH Cu+ + Toc• + H+
Toc• + AscH TocH + Asc•
Reaction 2
Reaction 3
Reaction 4
Reaction 5  
Scheme 1.1 Reaction schemes for the anti-oxidant and pro-oxidant activity of α-tocopherol 
The disadvantage to this anti-oxidant mechanism of α-tocopherol is that it is limited to the 
scavenging of already formed free radicals and hence may be regarded as a “symptomatic” 
rather than a causal approach in managing oxidative stress (Ceriello 2003). Several 
explanations have been given to account for the unpredictability of α-tocopherol in clinical 
trials despite favourable results in vitro. One such explanation is the potential of α-tocopherol 
to become a pro-oxidant in mild oxidative conditions (Celik et al. 2010). In mild oxidative 
conditions, if no free radical interacts with Toc
•
, it then directly oxidizes LDL PUFA moieties 
(LH) giving rise to the PUFA radical (L
•
) (Scheme 1.1, Reaction 3). Also when present in 
low amounts, Cu
2+
 directly interacts with TocH to form Toc
•
 (Scheme 1.1, Reaction 4). 
Hence, it appears that the fate of Toc
• 
plays a cardinal role in determining the anti-oxidant/ 
pro-oxidant activity ratio of α-tocopherol. In mild oxidative conditions, the use of α-
tocopherol co-anti-oxidants such as ascorbate (AscH) to recycle Toc
• 
back to TocH restores 
the anti-oxidant activity of α-tocopherol (Scheme 1.1, Reaction 5). However, under high 
oxidative stress conditions, α-tocopherol possesses anti-oxidant effects regardless of the 
concentration of AscH. Therefore, the anti-oxidant activity of α-tocopherol and other 
compounds bearing the same anti-oxidant mechanism as α-tocopherol is dependent on both 
the extent of oxidative stress as well as the concentration of co-anti-oxidants (Kontush et al. 
1996). Another explanation accounting for the unpredictability of α-tocopherol in clinical 
trials includes the existence of genetic polymorphisms in the expression of intrinsic anti-
oxidant enzymes (Celik et al. 2010). 
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Currently, the only conventional anti-diabetic agents known to have anti-oxidant properties 
are the thiazolidinediones (TZD’s), a class of drugs which act as PPARγ receptor agonists. 
Research has proven that the anti-oxidant activity of TZD’s is dependent on the activation of 
the PPARγ receptor (Chung et al. 2011) with the exception of rosiglitazone which, in addition 
to its PPARγ-dependent anti-oxidant activity, also exhibits a PPARγ-independent inhibition 
of glucose-induced ROS generation in QZG hepatocytes (Polvani Simone et al. 2012). In the 
research done by Chung et al., inhibition of PPARγ with a specific PPARγ antagonist GW-
9662 significantly reduced the anti-oxidant activity of TZD’s (Chung et al. 2011). The 
ligand-activated PPARγ receptor is thought to regulate the expression of various anti-oxidant 
and pro-oxidant genes such as MnSOD (a direct target of the PPARγ), Glutathione 
peroxidase 3 (GPx3), the mitochondrial uncoupling protein 2 (UCP2) and eNOS in response 
to oxidative stress (Polvani Simone et al. 2012). Therefore, unlike conventional anti-oxidants 
such as α-tocopherol which have a ‘causal’ approach in managing oxidative stress, the anti-
oxidant mechanism of PPARγ agonists has a ‘preventive’ approach. There is already much 
evidence from several studies warranting the ability of PPARγ agonists to prevent 
cardiovascular complications. PPARγ agonists also prevent atherogenesis and inflammation 
(Balakumar et al. 2007). This almost implies that PPARγ agonists are a potentially ideal class 
of anti-diabetic agents superior to the concurrent administration of hypoglycaemic agents 
with conventional anti-oxidants in the prevention of diabetic cardiovascular complications. 
However, current TZD’s are associated with weight gain, fluid accumulation, pulmonary 
oedema and macular oedema which ultimately results in congestive heart failure (Shearer and 
Billin 2007). Since PPARα agonists have been used to treat dyslipidemia via their effects on 
lowering free triglyceride concentrations in plasma, PPARγ side effects can be avoided by 
activating both PPARα and PPARγ at the same time resulting in increased metabolism of 
lipids and sensitivity of insulin (Kim et al. 2008). Because of this, several attempts have been 
made to develop PPARα/γ dual agonists. 
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1.5.3 Diabetes as an inflammatory process 
An abundance of evidence has emerged to demonstrate a close link between metabolism and 
immunity (Wellen and Hotamisligil 2005). Recently, much interest has been developed in the 
concept that prolonged low-grade inflammation and an activated innate immune system have 
a part to play in the cause of type II diabetes (Fernández-Real and Pickup 2008). The effects 
of hyperglycaemia on white blood cells such as polymorphonuclear leukocytes (PMN) 
contributes to the infections and prolonged inflammatory state associated with diabetes (Hand 
et al. 2007). Therefore, new methods of managing diabetes may be discovered by exploring 
inflammatory pathways and their inhibitory mechanisms (Fernández-Real and Pickup 2008). 
1.6 Anti-diabetic therapeutic agents 
Current anti-diabetic treatment aims at managing hyperglycaemia and attenuating the 
development of diabetic complications (Moller 2001). The current anti-diabetic agents are: 
Sulphonylureas and other insulin secretagogues such as meglitinides and GLP-1 analogues 
(which increase insulin secretion); dipeptidyl peptidase-4 (DPP-4) inhibitors (which increase 
incretin release causing glucagon inhibition and increased insulin secretion); metformin 
(which decreases glucose output from the liver); peroxisome proliferator-activated receptor-γ 
(PPAR-γ) agonists (thiazolidinediones, which increase the sensitivity of insulin); α-
glucosidase inhibitors (which prevent intestinal glucose uptake); and insulin (which decreases 
glucose output and increases cellular glucose usage) (Moller 2001). 
1.6.1 Structural classification of current anti-diabetic drugs 
Oral hypoglycaemic drugs are structurally classified as follows; 
1.6.1.1 Sulphonylureas 
IPTD Carbutamide  
Figure 1.6 Structures of IPTD and Carbutamide (Zavod and Krystenansky 2008) 
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The sulphonylureas were discovered in the 1950’s out of serendipity (Drews 2000). In the 
1940’s, 2-(p-aminobenzenesulfonamido)-5-isopropyl-thiadiazole (IPTD), a compound that 
was then used for the management of typhoid fever killed several patients by inducing acute 
and prolonged hypoglycaemia. However, IPTD never became an oral hypoglycaemic due to 
the discovery of a more effective drug called carbutamide. Carbutamide became the first 
marketed sulphonyurea (Drews 2000). 
 
 
 
Figure 1.7 The general structure of sulphonylureas 
The mechanism of action of sulphonylureas involves the stimulation of β-cell insulin 
secretion through the activation of ATP-sensitive potassium channels which are comprised of 
hetero-octameric complexes of two subunits: a sulphonylurea receptor (SUR1) and an 
inwardly rectifying potassium channel (Zavod and Krystenansky 2008). 
 
Figure 1.8 Selected structures of first, second and third generation sulphonylureas 
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Sulphonylureas have been classified as first, second and third generation. Tolbutamide (1.1) 
is a first generation sulphonylurea and the least potent oral hypoglycaemic agent due to its 
low SUR1 binding affinity. Due to its short half-life, tolbutamide is the most ideal 
sulphonylurea in senile diabetics and those experiencing moderate to severe kidney disease. 
Chlorpropamide (1.2), also a first generation sulphonylurea, is more potent and has a more 
prolonged action (mean elimination t½ 33 h). This is due to its slow metabolism in vivo 
owing to the p-Cl substituent which protects the p-position from metabolic oxidation. 
Tolazemide (1.3) is a first generation sulphonylurea with a more potent activity than 
Tolbutamide but a shorter duration of action than Chlorpropamide. Glibenclamide 
(Glyburide) (1.4) and Glipizide (1.5) are high potency second generation sulphonylureas with 
more complex Ar- moieties that facilitate receptor binding and influences their drug excretion 
profiles. Glimepiride (1.6) is a third generation sulphonylurea that was structurally derived 
from second-generation sulfonylureas by the exchange of an amide moiety with a 
heterocyclic group so that the drug could bind onto a different region of β-cell receptors and 
thereby enhancing its potency and increasing its duration of action. 
1.6.1.2 Meglitinides 
The meglitinides are a relatively new class of insulin secretagogues with repaglinide (1.7), 
the first drug to be classified under this group, approved for clinical use in 1998 (Nolte and 
Karam 2007). The mechanism of action of meglitinides involves increase in β-cell insulin 
secretion resulting from the regulation of potassium efflux through potassium channels. 
Meglitinides act similar to sulphonylureas because they interact with two binding sites that 
are common to sulphonylureas and one additional binding site (Nolte and Karam 2007). The 
structure of repaglinide (1.7) is characterized by the presence of the non-sulfonylurea moiety 
found in glibenclamide (1.4) and a salicylic acid derivative (Nattrass and Bailey 1999). 
Salicylates and sulfonylureas both reduce hyperglycaemia through different mechanisms. A 
derivative of D-phenylalanine, nateglinide (1.8) is related to repaglinide. Repaglinide can be 
used as monotherapy in combination with biguanides. Due to the lack of sulfur in its 
structure, repaglinide is idea for use in type II diabetics with sulfur or sulphonylurea allergies. 
Apart from its special role in isolated postprandial hyperglycaemia, nateglinide offers the 
lowest risk of hypoglycaemia of all secretagogues and is safe in patients with reduced renal 
function (Nolte and Karam 2007).  
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Figure 1.9 Structure derivatization of meglitinides 
1.6.1.3 Biguanides 
Galegine (isoamylenegaunidine) was discovered from the plant Galega officinalis (Goats rue 
of French lilac) as the main metabolite responsible for the death of grazing animals (Zavod 
and Krystenansky 2008). In 1918, guanidine was found to possess hypoglycaemic effects but 
was too toxic for therapeutic use. The biguanides phenformin (1.9, phenyethlbiguanide; 
withdrawn due to lactic acidosis), buformin (1.10) and metformin (1.11, dimethylguanide) 
are all guanidine derivatives introduced in the 1950’s as oral hypoglycaemics for the 
management of type II diabetes (Bailey 1992). The mechanism of action of biguanides 
involves the inhibition of hepatic glucagon dependent glucose output by decreasing the levels 
of cyclic AMP and the activity of protein kinase A (PKA) (Miller et al. 2013). 
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Figure 1.10 Structures of biguanides 
1.6.1.4 Gliptins (piperazine and cyanopyrrolidine derivatives) 
The gliptins are selective DPP-4 inhibitors that act by increasing the levels of incretin, a 
hormone with the key function of reducing prandial glucose excursions by increasing 
glucose-induced insulin secretion from the pancreatic β-cells. The main drugs in this group 
are: the piperazine derivative, sitagliptin (1.12); the cyanopyrrolidine derivative, vildagliptin 
(1.13) and the more recently introduced saxagliptin (Bailey and Krentz 2010). 
 
Figure 1.11 Structures of sitagliptin (1.12) and vildagliptin (1.13) 
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1.6.1.5 Thiazolidinediones (TZDs) 
The anti-diabetic activity of a TZD called ciglitazone was first reported in the early 1980’s. 
This was followed by the identification of the peroxisome proliferator-activated receptor 
(PPAR) family in the 1990’s and the discovery of TZDs as PPAR-γ agonists (Bailey and 
Krentz 2010). The expression of PPAR-γ receptors is mainly in adipose tissue though they 
are also expressed in muscles and the liver but to a lesser extent. Ligand activation of PPAR-
γ receptors results in the formation of heterodimeric complexes with retinoid X receptors 
which then bind to nucleotide sequences (AGGTCAXAGGTCA) referred to as peroxisome 
proliferator response elements (PPRE) that are located in the promoter regions of PPAR-
responsive genes (Bailey and Krentz 2010). This causes an alteration in the transcriptional 
activity of mainly the genes that are involved in lipid and carbohydrate metabolism. 
Stimulation of PPAR-γ by TZDs promotes the differentiation of preadipocytes into mature 
adipocytes which are highly sensitive to insulin (Bailey and Krentz 2010). TZDs include 
troglitazone (1.14, removed from the market due to hepatotoxicity), rosiglitazone (1.15), 
pioglitazone (1.16) and darglitazone (1.17). 
 
Figure 1.12 Selected structures of thiazolidinediones (TZDs) 
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1.6.1.6 α-Glucosidase inhibitors (oligosaccharides and polyols) 
This group of anti-diabetic drugs act by inhibiting α-glucosidase, an enzyme responsible for 
the final step of carbohydrate digestion. This inhibition subsequently delays the absorption of 
sugars. Arcabose (1.18), a pseudo-oligosaccharide, was the first α-glucosidase inhibitor to be 
introduced in the 1990’s followed by two agents; a simple aminosugar derivative called 
miglitol (1.19) and a simple amine substituted cyclohexane polyol called voglibose (1.20). 
The major limitation of α-glucosidase inhibitors is their tendency to cause gastro-intestinal 
side effects resulting from the fermentation of un-absorbed sugars in the gastro-intestinal tract 
(Bailey and Krentz 2010).  
 
Figure 1.13 Structures of α-glucosidase inhibitors 
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1.6.2 The search for new anti-diabetic lead compounds from natural sources 
Although research outcomes from randomized controlled trials indicate that the reduction of 
hyperglycemia also reduces the risk of diabetic micro-vascular complications, none of the 
currently available conventional drugs which aim at reducing hyperglycemia have 
convincingly demonstrated that they can significantly alter the progressive loss of pancreatic 
insulin secretion (Baynes 2006). Also, most of the current anti-diabetic drugs are now known 
to have limited efficacy and tolerability, significant mechanism-based side effects and the 
tendency to cause weight gain. Therefore, newer therapies with physiological response 
dependent mechanisms that do not cause weight gain are desperately needed (Moller 2001). 
One of the advantages of natural products over synthetic compounds is that they inherently 
contain a larger scale of structural diversity and hence, have become the major resource for 
the development of biologically active agents and the discovery of lead compounds (Liu et al. 
2010). Current anti-diabetic agents were developed without proper knowledge of the relevant 
molecular targets or understanding of the disease pathogenesis. However, the understanding 
of biochemical pathways related to the development of diabetes has since increased (Moller 
2001). Mechanistic categories for new therapeutic approaches include those that aim at; 
reducting hepatic glucose production, increasing glucose-stimulated insulin secretion, 
molecular targeting of insulin signalling pathways and improving insulin action or secretion 
(Moller 2001). 
1.6.2.1 Terrestrial plant-derived potential anti-diabetic compounds 
In combination, traditional treatments for diabetes mellitus and investigative studies on 
potential anti-diabetic (hypoglycaemic) agents have utilized over 1200 species of plants 
(Marles and Farnsworth 1995). Deoxyelephantopin (1.21, ESD), a sesquiterpene lactone 
isolated from the plant Elephantopus carolinianus, is a selective partial agonist for PPAR-γ 
which adopts a distinct PPAR-γ binding mode to that of rosiglitazone as determined by 
molecular modeling (Zou et al. 2008). Ursolic acid (1.22), a pentacyclic triterpenoid isolated 
from the fruits of a Chinese medicinal plant Cornus officinalis, and its synthetic derivative 
compound UA0713 (1.23) are both protein tyrosine phosphatase 1B (PTP1B) inhibitors 
(Zhang et al. 2006). Resveratrol (RSV), a natural polyphenolic compound isolated from the 
skin of Vitis vinifera (red grapes), is an allosteric SIRT1 activator that mimics the effects of 
calorie restriction, reduces blood glucose and insulin levels and ameliorates insulin resistance 
22 
 
(Lagouge et al. 2006). Based on RSV, SIRT1 activators 1000-fold more potent than RSV 
were identified (Liu et al. 2010).  
 
Figure 1.14 Selected structures of plant-derived potential anti-diabetic compounds 
1.6.2.2 Marine algae-derived potential anti-diabetic compounds 
According to El Gamal (2010), “marine organisms are potentially prolific sources of highly 
bio-active secondary metabolites that might represent useful leads in the development of lead 
pharmaceutical agents”. Several novel compounds possessing interesting biological activity 
have been isolated from marine organisms (El Gamal 2010). Such compounds include 1,2-
bis(2,3,6-tribromo-4,5-dihydroxyphenyl)-ethane (1.25, IC50 = 3.5 µmol/L), a PTP1B inhibitor 
isolated from the brown algae Symphyocladia latiuscula (Liu et al. 2011). 
Hydroxyisoavrainvilleol (1.26), another PTP1B inhibitor, has been isolated from the tropical 
green algae Avrainvillea nigricans as well as the red algae Polysiphonia urceolata (El Gamal 
2010). Several Bromophenols of algal origin have shown α-glucosidase inhibitory activity. 
Such compounds include bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (1.27), purified from 
the red alga Polyopes lancifolia with activity against Saccharomyces cerevisiae and Bacillus 
stearothermophilus α-glucosidases (IC50 values of 0.098 μM and 0.120 μM respectively) 
(Kim et al. 2010). Octaphlorethol A (1.28), a phenolic compound sourced from the brown 
alga Ishige foliacea, has helped to identify PI3K/Akt activation and the AMPK signalling 
pathway as a new therapeutic target in the management of type II diabetes by its ability to 
increase glucose uptake via the GLUT4 receptor (Lee et al. 2012). 
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Figure 1.15 Selected structures of marine-derived potential anti-diabetic compounds 
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1.7 Research objectives 
The need for newer compounds in the management of diabetes and the prevention of its 
complications cannot be over-emphasized. We have theoretically established that anti-oxidant 
compounds that reduce the accumulation of toxic metabolites of glucose such as free radicals 
may prevent diabetic complications. Such compounds offer an advantage because the 
management of diabetes would then also concentrate on the prevention of long term free 
radical accumulation instead of only focusing on the control of glycaemic levels. Therefore, 
any treatment approach that combines hypoglycaemic effects with prevention of free radical 
generation is far much better than one that only focuses on hypoglycaemic effects in 
preventing diabetic complications. 
The aim of this research project is to discover anti-oxidant compounds from marine algae 
with potential anti-diabetic activity. An ideal anti-diabetic compound in this case would be 
one that, in addition to hypoglycaemic activity, would in low concentrations relative to the 
substrate to be oxidized, exhibit anti-oxidant activity by being able to delay, retard or prevent 
either auto-oxidation or free radical-mediated oxidation. This type of compound will 
hopefully be achieved by the following: 
(i) Performing a literature review of marine algae reported to have anti-oxidant activity 
(ii) Screening of the selected marine algae 
(iii) Bioactivity guided isolation of anti-oxidant/anti-diabetic natural products 
(iv) Structural characterization of the natural products and synthetic analogues 
(v) In-vitro anti-oxidant/anti-diabetic evaluation of the natural products and synthetic 
analogues 
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Chapter 2 
In-vitro screening of selected South African marine algae 
2.1 Introduction 
Current paradigms in the development of new drug entities focus on obtaining a high 
molecular diversity that maintains reasonable drug-like properties (Koehn and Carter 2005). 
In this approach to drug discovery, natural products show a higher promise over synthetic and 
combinatorial compounds because they are chemically diverse and biochemically specific 
(Koehn and Carter 2005). The exploration of natural products that possess anti-oxidant 
activity and prevent oxidative damage is important for the discovery and development of new 
treatment strategies against obesity-related diseases such as diabetes mellitus (Lee et al. 
2011). Similar to other photosynthesizing plants, exposure of marine algae to intense light 
and high oxygen concentrations results in the generation of free radicals and other strong 
oxidizing agents (Nahas et al. 2007). The fact that marine algae remain stable during storage 
with no signs of oxidative damage in their structural components suggests the presence of 
protective anti-oxidant systems (Nahas et al. 2007). Through the protection of cells from 
oxidative damage, marine-derived anti-oxidants have shown their importance as bioactive 
compounds against oxidative stress related diseases (Kelman Dovi et al. 2012). 
2.1.1 Selection of South Africa endemic marine algae for screening 
In order to achieve the aim of discovering marine derived potential anti-diabetic compounds 
with preliminary anti-oxidant activity, we performed a literature search for marine algae from 
specific algal genera that have been documented to possess anti-oxidant activity. We 
achieved this by investigating species of algal genera from which anti-oxidant compounds 
have been previously isolated. Such anti-oxidant compounds include the phenolics taondiol 
(2.1), stypodiol (2.2), stypoldione (2.3) and atomaric acid (2.4) (Figure 2.2) isolated from the 
Aegean brown sea weed Taonia atomaria (Nahas et al. 2007). These compounds were also 
previously isolated from the alga Stypopodium zonale collected in Spain (Wessels et al. 
1999). However, the South African S. zonale has not yet been studied. Since species of the 
genus Stypopodium are not easily morphologically distinguished from those of Taonia, this 
suggests a possible botanical misidentification of the Canarian T. atomaria with the 
likelihood that T. atomaria from the Canary Islands is in reality S. zonale (Soares et al. 2003). 
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The genus Dictyopteris is known to produce sulphated polysaccharides with superoxide 
radical scavenging activity such as those from Dictyopteris delicatula (Costa et al. 2010). 
These sulphated polysaccharides include several fucoidans isolated from the brown algae 
Dictyopteris polypodioides (Sokolova et al. 2011). 
Cystophora and Cystoseira, the two major genera of the Cystoseiraceae family, are known 
for their production of relatively complex meroditerpenoids. Cystophora produces both 
isoprenoid and non-isoprenoid secondary metabolites with various functionalised carbon 
skeletons characterized by linear and cyclic C18 terpenoid metabolites (Reddy and Urban 
2008). The Australian brown algae Cystophora moniliformis produces farnesylacetone 
derivatives (2.5) and (2.6) (Figure 2.2) (Reddy and Urban 2008), also isolated from the 
honey bee entomopathogenic fungus Ascosphaera apis, with reported anti-oxidant activity 
(Gallardo et al. 2008). There are three main classifications to the Cystoseira genus 
designated as categories A-C. These categories are mainly based on the type of 
metabolites produced. The metabolites produced from category A do not contain 
diterpenes while those from category B possess linear diterpenes. The metabolites 
produced from category C are either linear, cyclic or rearranged meroditerpenoids (Reddy 
and Urban 2008). Triprenyltoluquinols such as (2.7) (occurring either as an E′ or Z′ isomer 
on the position indicated by the wavy bond in Figure 2.2) and tetraprenyltoluquinols such 
as (2.8) (Figure 2.2) both isolated from Cystoseira crinite exhibit DPPH and TBARS 
radical scavenging anti-oxidant activity (Reddy 2009). Six cyclised tetraprenyltoluquinols 
and five stereoisomers were previously isolated from the South African species 
Cystophora fibrosa with the same amentol skeleton as the compounds isolated from the 
species C. crinite (Laird and van Altena 2006). 
From the Cystoceiraceae family are found the genera Bifurcaria and Bifurcariopsis. The 
main species arising from Bifurcaria are: B. bifurcata, found on Atlantic coasts; B. 
brassicaeformis, found on western and Indian Ocean coasts of South Africa; and B. 
galapagensis. A rich array of acyclic diterpenes have been previously isolated from B. 
bifurcata (Daoudi et al. 2001) and crude extracts of the algae have shown marked DPPH 
radical scavenging activity (Zubia et al. 2009). The genus Bifurcariopsis is monotypic and 
the generitype B. capensis is known only from South Africa (Daoudi et al. 2001). 
However, the key metabolites responsible for the anti-oxidant activity of B. bifurcata have 
not yet been identified. 
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Several species of the genus Sargassum have shown radical scavenging effects 
(Budhiyanti et al. 2012). A chromene mojabanchromanol (2.9) isolated from Sargassum 
siliquastrum possesses remarkable anti-oxidant activity (Cho et al. 2008). The 
tetraprenyltoluquinols thunbergol A (2.10) and thunbergol B (2.11) (Figure 2.2) isolated 
from S. thunbergii both exhibit significant radical scavenging activity and inhibition of 
morpholinosydnonimine (Linsidomine or SIN-1) generated peroxynitrite (Seo et al. 2006). 
Similar prenylated toluquinols have been isolated from the South African genus S. 
heterophyllum (Afolayan et al. 2008). 
During the selection of algae for screening studies, we were constrained by lack of access. 
Hence, we focused on those algae that were accessible and could be collected in 
reasonable quantities, many of which were endemic to South Africa and had not been 
extensively studied. The algae that were selected are: Stypopodium zonale (a), 
Dictyopteris ligulata (b), Cystophora fibrosa (c), Bifurcariopsis capensis (d), Sargassum 
sp. (e) and Sargassum heterophyllum (f) (Figure 2.1). 
 
 
Figure 2.1  Images of S. zonale (a), D. ligulata (b), C. fibrosa (c), B. capensis (d), 
Sargassum sp. (e) and S. heterophyllum (f) (Guiry and Guiry 2012) 
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Figure 2.2 A selection of anti-oxidant compounds isolated from various algal species 
2.2 Anti-oxidant/radical scavenging screening of crude algal extracts and fractions 
In our search for potential anti-oxidant/radical scavenging compounds, it is of great 
importance to emphasize that radical scavenging activity does not fully guarantee anti-
oxidant activity. According to Tirzitis and Bartosz (2010), “antiradical activity is 
characterised by the ability of a compound or extract to react with and thereby neutralize free 
radicals while anti-oxidant activity represents the ability to inhibit the process of oxidation” 
(Tirzitis and Bartosz 2010). The general methods employed in the determination of anti-
oxidant/radical scavenging activity include the 2,2-azinobis (3-ethyl-benzothiazoline-6-
sulfonic acid) (ABTS), the 2,2-diphenyl-1-picrylhydrazyl (DPPH), the ferric reducing 
antioxidant power (FRAP) and the oxygen radical absorption capacity (ORAC) assays 
(Thaipong et al. 2006). In this study, we employed the DPPH assay because of its cost 
effectiveness and high reproducibility. The FRAP assay is equally as reproducible as the 
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DPPH assay but we could not use this method because our test samples were insoluble in 
FRAP reagent. Besides the ORAC assay being an expensive alternative due to the 
involvement of expensive equipment, the ABTS and ORAC assays are relatively less 
reproducible than the FRAP and DPPH assays (Thaipong et al. 2006). 
2.2.1 The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical assay 
The DPPH assay has been described as a simple, rapid and convenient method independent 
of sample polarity for the screening of radical scavenging activity (Marxen et al. 2007). The 
purple coloured diphenylpicrylhydrazyl (2.12) free radical is stable in methanolic solution. In 
the presence of a potent anti-oxidant/radical scavenging compound or extract, purple 
coloured diphenylpicrylhydrazyl radical is spontaneously converted to yellow coloured 
diphenylpicrylhydrazine (2.13) with an absorbance maximum centred at about 520 nm 
(Marxen et al. 2007). This assay is based on the principle that accepting a hydrogen atom 
from an anti-oxidant agent results in the reduction of the hydrazyl radical to form the 
hydrazine stable compound with a concomitant decrease in absorbance at 513 nm. It is 
important to emphasise that this mechanism of hydrogen atom transfer is different from that 
of biological radical scavenging which occurs through electron transfer. 
 
Figure 2.3 Anti-oxidant mediated conversion of diphenylpicrylhydrazyl (2.12) (purple) to 
diphenylpicrylhydrazine (2.3) (yellow) 
·R= Hydrogen radical donated from anti-oxidant compound/extract 
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2.3 Anti-inflammatory assay 
Macrophages represent a highly heterogeneous group of hematopoietic cells present in almost 
all tissues including adipose. When microphages are triggered by stimuli, their response can 
be categorized into two distinct and mutually exclusive activation programs known as 
classical and alternative. Classical activation causes a highly inflammatory phenotype and 
mainly occurs in response to bacterial stimuli such as lipopolysaccharide (LPS) and 
interferon gamma (IFN-γ). The classically activated macrophages then produce a myriad of 
pro-inflammatory signals which can alter the functionality of its surrounding cells. In 
addition, these activated cells produce various highly reactive oxidants including nitric oxide 
(NO), a product of the catalysis of arginine by the enzyme inducible nitric oxide synthase 
(iNOS). Therefore, the production of NO and consequent nitrate accumulation is 
conveniently used as a marker for classically activated macrophages. 
Adipose tissue contains both adipocytes and resident macrophages which can produce 
cytokines. Pro-inflammatory cytokines derived from adipose tissue contribute to the 
pathogenesis of insulin resistance via changes in the phosphorylation status of IRS1 in the 
insulin signalling cascade. Numerous studies have demonstrated increased accumulation of 
macrophages in adipose tissue of obesity models of metabolic syndrome. Hence, the 
inhibition of an inflammatory response represents a potential therapeutic target to treat 
obesity related type II diabetes. 
2.4 In-vitro cytotoxicity assays 
Cell based in-vitro cytotoxicity assays are generally designed for studying individual 
compounds of known structure and concentration.  It is important to keep in mind that cell 
based cytotoxicity analysis of botanical or natural extracts are difficult to interpret in terms of 
predicting toxicity in vivo, because these extracts contain mixtures of compounds and their 
concentrations will differ depending on which compounds reach the liver or other organs 
after oral administration. 
Cytotoxicity assays are used as the first phase in anti-diabetic screening to evaluate the 
suitability of the test samples for in vitro cell based assays. This includes establishing 
parameters such as solubility in culture medium and general cellular toxicity profiling. For 
samples with poor aqueous solubility it is difficult to establish accurate dose response curves 
as higher doses do not produce the expected higher response. Similarly there is a high 
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likelihood that basal toxicity of the samples can disguise the anti-diabetic potential of any 
active constituents within the extract. Together, these factors define the practical limits within 
which the anti-diabetic data can be interpreted. 
2.4.1 The Chang Liver cell line 
The Chang liver cell line originated from a normal liver obtained from a Chinese boy (Chang 
Shih-man 1954) and was later transformed in-vitro. Controversy exists in literature regarding 
the current authenticity of the Chang Liver cell line as it is believed to have been 
contaminated by HeLa cells prior to its deposition in cell banks such as the American Type 
Culture Collection (ATCC) (Masters 2002). The presence of HeLa markers (DNA sequences) 
and the absence of PCR amplifiable Y chromosome DNA sequences are considered as 
evidence that these cells now represent a derivative of HeLa cells. Despite these findings, 
there are a number of publications which suggest that these cells possess characteristics 
associated with hepatocyte function (Ludueña et al. 1977). Therefore, the use of this cell line 
as a model for normal human liver should be interpreted with caution as we have no 
definitive proof as to the authenticity of our Chang liver cell line. On the other hand, even if 
they do not represent hepatocytes, Chang Liver cells provide an acceptable model to explore 
general cellular cytotoxicity as many of the known drug induced cytotoxic mechanisms such 
as those involving mitochondrial function, calcium levels, cellular death pathways, free 
radical accumulation, enzymatic activity, cellular transportation and generation of harmful 
metabolites are common to most cells. 
2.4.2 The HT-29 and Caco-2 cell lines 
The HT-29 and Caco-2 are human colon carcinoma cell lines established by Jorgen Fogh in 
1964 and 1974 respectively (Rousset 1986). These cells have gained increased interest due to 
their ability to express differentiation features characteristic of mature intestinal cells such as 
enterocytes or mucus cells. Because of these characteristics, HT-29 and Caco-2 cell lines 
have been used in various fields of investigation related to intestinal cell differentiation, 
function and malignant transformation (Rousset 1986). In this study, our main rationale for 
the use of these cell lines is not based on the aforementioned characteristics but rather to 
explore the cytotoxicity profiles of our extracts and fractions against both normal and 
malignant cells. However, outside the scope of this research, selective cytotoxicity of any of 
our test samples towards a particular malignant cell line is indicative of the need for its 
further research in that particular pathology. 
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2.4.3 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
A modification of the original MTT assay (Mosmann 1983) was used to evaluate the 
cytotoxicity of the extracts. MTT (2.14) is a yellow tetrazolium salt which is converted by 
dehydrogenase enzymes in viable cells to an insoluble purple compound called formazan 
resulting from the cleavage of the tetrazolium ring. The amount of purple formazan that is 
extracted from the cells is proportional to the number of viable cells. Since the assay 
quantifies the number of viable cells at the end of the treatment period, it is not possible to 
distinguish between treatments that have a cytotoxic (cell killing) or cytostatic (cell growth 
inhibiting) effects. It has been shown that plant extracts with strong anti-oxidant activity can 
also convert MTT to the purple formazan (Muraina et al. 2009) thereby masking cytotoxic 
effects. To avoid this, the cells are incubated with the extract for 48 hours after which the 
extract is removed from the cells before the addition of MTT. 
 
Figure 2.4 The structure of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT, 2.14) 
2.5 Chapter aims 
In Chapter one, we described the diabetic state as a low-grade inflammatory process  and 
explained the significant role that free radical mediated oxidative stress plays in the 
pathophysiology of the disease. We also discussed the potential role of anti-oxidants in the 
management of type II diabetes mellitus. This chapter aims at identifying and screening 
various marine algae for anti-oxidant and anti-inflammatory activity and further evaluating 
their potential in-vitro cytotoxicity. 
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2.6 Results and Discussion 
2.6.1 Collection and extraction of South African algae 
Stypopodium zonale (DH110218-1), Dictyopteris ligulata (DH110218-2), Cystophora 
fibrosa (DH110218-3), Bifurcariopsis capensis (DH110218-4) and Sargassum sp. were 
collected from De Hoop near Cape Town while Sargassum heterophyllum (NDK101124) 
was collected from Noordhoek near Port Elizabeth. 
A standard procedure was implemented for the extraction of the algae. The algal biomasses 
were extracted with MeOH followed by DCM/MeOH (2:1). The extracts of each alga were 
then combined and sufficient deionised water was added to allow separation of the aqueous 
MeOH and CH2Cl2 phases. The desired crude extracts for S. zonale (MN-11-8a, 362.7 mg), 
D. ligulata (MN-11-8b, 467.1 mg), C. fibrosa (MN-11-8c, 778.6mg), B. capensis (MN-11-
8d, 1331 g), Sargassum sp. (MN-11-8e, 69.1 mg) and S. heterophyllum (MN-11-62, 1240 
mg) were obtained after concentration of the CH2Cl2 phase under rotary evaporation. 
2.6.2 DPPH Anti-oxidant/radical scavenging activity of algal extracts 
The DPPH anti-oxidant/radical scavenging activity of the crude extracts varied from 
undetectable to that nearly equivalent to ascorbic acid. From the results, extracts from S. 
heterophyllum (MN-11-62, IC50 = 20.93 µg/mL) and B. capensis (MN-11-8d, IC50 = 27.10 
µg/mL) showed the most potent DPPH radical scavenging activity. S. heterophyllum (MN-
11-62) exhibited a higher DPPH radical scavenging activity than that of ascorbic acid (IC50 = 
24.07 µg/mL) while C. fibrosa (MN-11-8e) did not show any activity at all the test 
concentrations. The anti-oxidant activity of the Sargassum genera has been reported in 
literature. Examples of Sargassum species that have shown potent anti-oxidant activity 
include extracts from S. hystrix, (Budhiyanti et al. 2012), S. boveanum (Zahra et al. 2007) and 
S. spagiophyllum (Suresh et al. 2012). However, this account is the first to report the anti-
oxidant activity of extracts from B. capensis. 
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Table 2.1 IC50 values for the DPPH radical scavenging activity of S. zonale (8a), D. 
ligulata (8b), C. fibrosa (8c), B. capensis (8d), Sargassum sp. (8e) and S. 
heterophyllum (62) crude extracts 
Crude Extract IC50 (µg/mL) 
Ascorbic acid 24.07 
8a 48.95 
8b 254.7 
8c 72.61 
8d 27.10 
8e 0.00 
62 20.93 
 
2.6.3 Potential Anti-inflammatory activity of algal extracts 
Stimulation of RAW267.4 cells with bacterial LPS (1 μg/mL) resulted in a greater than 200 
fold increase in the production of nitrate, indicating classical activation to the inflammatory 
phenotype.  Aminoguanidine, an inhibitor of both iNOS activity and its expression strongly 
inhibited nitrate production.  D. ligulata (8b) showed pro-inflammatory activity by increasing 
nitrate production in the absence of LPS (Figure 2.5). Pro-inflammatory activity will 
normally risk an exacerbated inflammatory response. With the exception of D. ligulata (8b), 
there was no significant pro-inflammatory activity observed in the rest of the algal extracts. 
Significant inhibition of nitrate production was evident in crude extracts of C. fibrosa (8c), 
Sargassum sp. (8e) and S. heterophyllum (62), with the latter having significant inhibitory 
activity at both test concentrations (12.5 and 25 μg/mL). These effects also appear to be 
independent of toxicity as revealed through corresponding maintenance of cell viability as 
assayed using MTT. Anti-inflammatory activity by inhibition of nitrate production in murine 
RAW 264.7 macrophages has been reported in extracts from the Sargassum specie, S. 
thunbergii (Yang et al. 2010). The anti-inflammatory activity of the Cystophora specie, C. 
torulosa, has also been previously documented (Baker 1984). To our knowledge, there has 
not been any previous report documenting the potential pro-inflammatory activity of D. 
ligulata (8b). 
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Figure 2.5 Nitrate production and cell viability in murine macrophages (RAW264.7) treated with S. zonale (8a), D. ligulata (8b), C. fibrosa 
(8c), B. capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts. 
Significant (p<0.05) reductions in the levels of nitrate are indicated as (*) 
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2.6.4 Cytotoxicity profiles of the crude algal extracts 
There are two main reasons for the assessment of the toxicity of a compound/extract prior to 
in-vitro anti-diabetic testing. Firstly, toxic effects tend to override the anti-diabetic endpoints 
thereby creating difficulty in the accurate assessment of anti-diabetic properties.  Secondly, 
when attempting to establish an anti-diabetic dose response, severe toxicity at high doses 
gives rise to a negative trend. Samples which display EC50 values below 100 μg/mL in Chang 
liver cells may not to be suitable for cell based assays without the consideration of lowering 
the test concentrations. Although it is possible to do so, it is also important to bear in mind 
that the sensitivity of the assay methods may become limiting. The individual EC50 values for 
the crude extracts are presented in Table 2.2. 
Table 2.2 EC50 values for S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. capensis 
(8d), Sargassum sp. (8e) and S. heterophyllum (62) crude extracts against 
Chang liver, HT-29 and Caco-2 cells as obtained using the MTT assay 
 
Sample code 
 
EC50 Chang Liver 
(μg/mL) 
 
EC50 HT-29 
(μg/mL) 
 
EC50 Caco-2 
(μg/mL) 
α-tocopherol >500 ND ND 
8a 61.67 92.47 73.12 
8b 150.7 19.55 27.08 
8c 21.79 36.6 31.73 
8d > 500 >500 >500 
8e 139.9 >500 >500 
62 15.31 71.5 63.8 
ND = not determined 
From the results and as expected, the positive control α-tocopherol displayed no cytotoxicity 
(EC50 > 500 μg/mL) towards Chang liver cells (Table 2.1). With EC50 values > 500 μg/mL 
for all cell lines, B. capensis (8d) did not show any cytotoxicity. Sargassum sp. (8e) had no 
cytotoxicity towards HT-29 and Caco-2 cells (EC50 > 500 μg/mL) but had selective 
cytotoxicity towards Chang liver cells (EC50 = 139.9 μg/mL). D. ligulata (8b) was generally 
cytotoxic towards all cell lines but with relatively less cytotoxicity towards Chang liver cells 
(EC50 = 150.7 μg/mL). The cytotoxic activity of polysaccharides isolated from Dictyopteris 
species such as D. polypodioides has been previously reported (Sokolova et al. 2011). C. 
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fibrosa (8c) was relatively more cytotoxic than the rest of the algae with EC50 values of 
21.79, 36.6 and 31.73 μg/mL against Chang liver, HT-29 and Caco-2 cell lines respectively. 
The cytotoxicity of algae from the Cystophora genus has been reported in literature. Such 
examples include the antitumoural activity of the tetraprenyl toluquinols usneoidol Z and 
Usneoidol E isolated from Cystophora usneoides (Urones et al. 1992). S. heterophyllum (62) 
was also generally cytotoxic to all cell lines with selective cytotoxicity towards Chang liver 
cells (EC50 = 15.31 μg/mL). The cytotoxicity of S. zonale (8a) had a similar profile towards 
all cell lines with no signs of selectivity.  
In this chapter, we managed to identify and screen various marine algae for anti-oxidant and 
anti-inflammatory activity and further evaluated their potential in-vitro cytotoxicity. From the 
identified algae, we determined that extracts from S. heterophyllum (MN-11-62, IC50 = 20.93 
µg/mL) and B. capensis (MN-11-8d, IC50 = 27.10 µg/mL) had the most potent DPPH radical 
scavenging activity. We also established that among the crude extracts that inhibited nitrate 
production in murine macrophages, S. heterophyllum (62) possessed the highest anti-
inflammatory activity. From the screened algae, crude extracts of B. capensis and Sargassum 
sp. had the least cytotoxicity towards the tested cell lines. By exhibiting the most potent anti-
oxidant/radical scavenging and anti-inflammatory activity, S. heterophyllum crude extract 
showed the highest promise for bio-active compounds relevant to diabetes mellitus. 
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2.7 Experimental 
2.7.1 General experimental 
All solvents used were analytical grade without need for further purification from commercial 
sources. Extraction solvents and culture mediums were sourced from Sigma Aldrich® and 
Hyclone® respectively. The EC50 values of each extract were calculated from a minimum 5-
point dose response curve using GraphPad Prism 4 software package. 
2.7.2 Algal Material 
Stypopodium zonale (DH110218-1), Dictyopteris ligulata (DH110218-2), Cystophora 
fibrosa (DH110218-3), Bifurcariopsis capensis (DH110218-4) and Sargassum sp. were 
collected from De Hoop near Cape Town while Sargassum heterophyllum (NDK101124) 
was collected from Noordhoek near Port Elizabeth. The algae were transported to the 
laboratory in ice, frozen and stored at – 4 oC until the time of extraction. Sample 
authentication was done by anatomical comparison with voucher specimens at the Division of 
Pharmaceutical Chemistry, Rhodes University, Grahamstown, South Africa. 
2.7.3 Extraction of marine algae 
After defrosting under running water, the Stypopodium zonale (DH110218-1) biomass was 
soaked in MeOH for 30 min after which the MeOH was decanted and the retained algae 
heated at 40 
o
C for 30 min in CH2Cl2/MeOH (2:1). MeOH and CH2Cl2/MeOH mixtures were 
pooled and sufficient deionised water added to allow phase separation of the CH2Cl2 and the 
MeOH/H2O phases. The CH2Cl2 phase was then collected separately and dried in vacuo to 
yield the desired crude extract (MN-11-8a, 362.7 mg). 
Dictyopteris ligulata (DH110218-2), Cystophora fibrosa (DH110218-3) and Bifurcariopsis 
capensis (DH110218-4) biomasses were blended in MeOH. CH2Cl2 was further added and 
the CH2Cl2/MeOH (2:1) mixture heated at 40 
o
C. MeOH and CH2Cl2/MeOH mixtures were 
pooled and sufficient deionised water added to allow phase separation of the CH2Cl2 and the 
MeOH/H2O phases. The CH2Cl2 phase was then collected separately and dried in vacuo to 
yield the desired crude extracts MN-11-42a (Dictyopteris ligulata), MN-11-41a (Cystophora 
fibrosa) and MN-11-43a (Bifurcariopsis capensis). 
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The Sargasssum heterophyllum (NDK101124) biomass was soaked in MeOH for 1 h after 
which the MeOH was decanted and the retained algae heated at 40 
o
C for 30 mins in 
CH2Cl2/MeOH 2:1. The MeOH and CH2Cl2/MeOH mixtures were then pooled and sufficient 
deionized water added to allow phase separation of the CH2Cl2 and the MeOH/H2O phases. 
The CH2Cl2 phase was then collected separately and dried in vacuo to yield the desired crude 
extract (MN-11-62, 12.4g). 
2.7.4 Sample preparation for in-vitro assays 
The dried extracts were reconstituted in DMSO to 100 μg/μL and then diluted with complete 
medium to the desired test concentrations. The final DMSO content in the assays was kept 
below 1%, a concentration with minimal effect on cell viability. 
2.7.5 The DPPH Anti-oxidant assay 
The test samples were diluted in EtOH/H2O (1:1) from 10 mg/100 μL stocks prepared in 
DMSO. 5 μL of each sample was pipetted into individual wells of a 96-well plate and then a 
120 μL of Tris-HCl buffer (50 mM, pH7.4) was added followed by 120 μL of freshly 
prepared DPPH solution (0.1 mM in ethanol). The plate was incubated for 20 min at room 
temperature and the absorbance read at 513 nm. The percentage of DPPH scavenging was 
calculated as [(A- B/A) × 100], where A represents absorbance without test samples and B 
represents absorbance in the presence of test samples. Ascorbic acid was used as a positive 
control (EC50 = 24.07 μg/mL). 
2.7.6 Anti-inflammatory assay 
The murine peritoneal macrophage cells (RAW267.4) were cultured in DMEM containing 
10% FCS from LONZA
®
. Cells were seeded into 96 well plates at a density of 8 X 10
4
 
cells/well and allowed to attach overnight. The cells were then treated with 1 μg/mL LPS 
(SIGMA
®
) and two concentrations of test sample (12.5 and 25 μg/mL) for 18 h. To measure 
nitrate levels, 50 μL of the spent culture medium was removed and added to an equal volume 
of Griess reagent (SIGMA
®
). The absorbance was measured at 540 nm using a microplate 
reader and the nitrate concentrations were calculated by comparison with the absorbance to 
sodium nitrate standard solutions. Aminogaunidine (SIGMA
®
) was used as positive control 
to demonstrate the inhibition of nitrate production. Cell viability was simultaneously 
measured using the standard MTT assay. 
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2.7.7 In-vitro Cytotoxicity assays 
The Chang liver cells were seeded into 96-well culture plates (TTP) at 10 000 cells/well in 
EMEM supplemented with 10% fetal bovine serum (FBS) and left for 24 hrs. Algal extracts 
were added and the cells incubated for a further 48 hrs after which the medium was replaced 
with 200 μL of MTT (Sigma®) (0.5 mg/mL in EMEM). After a further 2 hrs of incubation at 
37 °C, the MTT was removed and the purple formazan product dissolved in 200 μL of 
DMSO. 
The HT-29 and Caco-2 cells were seeded into 96-well culture plates (TTP) at 5 000 cells/well 
in DMEM supplemented with 10% fetal bovine serum (FBS) and left for 24 hours. Algal 
extracts were added and the cells incubated for a further 48 hrs after which the medium was 
replaced with 200 μL MTT (Sigma®) (0.5 mg/mL in DMEM). After 3 hrs of incubation at 37 
°C, the MTT was removed and the purple formazan product dissolved in 200 μL DMSO. 
The absorbance was measured at 560 nm using a multiwell scanning spectrophotometer 
(Multiscan MS, Labsystems). All incubation steps were carried out in a 37 °C humidified 
incubator with 5% CO2. EC50 values were calculated from a minimum 5-point dose response 
curves using GraphPad Prism 4 software package. 
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Chapter 3 
Isolation and synthetic modification of prenylated toluhydroquinone and 
toluquinone metabolites from Sargassum heterophyllum 
3.1  Introduction 
Plant derived natural products form the basis of sophisticated traditional medicine systems 
that have been in existence for thousands of years (Cragg and Newman 2005). In some parts 
of the world, natural remedies are still the only treatment available. Conventional drugs are 
either extracted from natural sources or synthesized using natural compounds as templates or 
precursors (Pomponi 2001). With the discovery of over 21,855 marine-derived compounds 
possessing novel mechanisms of action (Blunt et al. 2013), the unexplored marine 
environment harbours the vastest biological and chemical diversity (Lui 2012). Marine 
macroalgae, or ‘seaweeds’ as they are most generally called, have been used as crude drugs 
for vitamin supplementation, in the treatment of iodine deficiency states, in the management 
of pregnancy associated anaemia, for the alleviation of various intestinal disorders and as 
hypocholesterolaemic and hypoglycaemic agents with the latter property claimed for the 
seaweeds Cystoseira barbata, Sargassum confusum and Junia rubens (Blunden 2002). The 
potential of marine natural products to compete with synthetic compounds as future 
pharmaceuticals and their contribution to the cure of human disease will depend on their 
increased isolation from natural sources, the development of new technologies and efficient 
collaborations between multi-disciplinary scientists (Lui 2012). 
3.1.1 Marine pharmacognosy of the Sargassum C. Agardh genus 
Sargassum C. Agardh is one of the marine macroalgal genera from the class Phaeophyceae 
(brown algae). This genus is present in much of the tropics and has been described as large, 
economically important and ecologically dominant (Marimuthu et al. 2012). The 
Phaeophyceae has five recognized subgenera: Phyllotrichia (Areschoung) J. Agardh, 
Schizophycus J. Agardh, Bactrophycus J. Agardh, Arthrophycus J. Agardh and Sargassum 
(Stiger et al. 2000). Sargassum C. Agardh is the largest genus within the Phaeophyceae and 
includes more than 400 described species that are globally distributed in tropical and 
subtropical regions (Stiger et al. 2000). Phytochemistry studies have only been reported on an 
estimate of 62 species of the Sargassum genus (Reddy 2009). 
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The east coast of South Africa is characterised by a high wave-energy environment and one 
of its most common genera of intertidal algae is S. crassifolium, S. elegans, S. heterophyllum, 
S. lendigerum and S. obovatum (Critchley et al. 1991). According to Stiger et al., “the 
taxonomy of the Sargassum genera has been regarded as notoriously difficult due to 
morphological plasticity” (Stiger et al. 2000). S. heterophyllum possesses a large discoid 
holdfast for attachment which gives rise to a main axis. The main axis gives rise to primary 
laterals which float due to the presence of vesicles filled with air and partitioned into 
receptacle producing laterals. The receptacles produced by these laterals possess gametangia 
inside their male and female conceptacles. The presence of both male and female 
conceptacles makes S. heterophyllum receptacles to be androgenous (Critchley et al. 1991). 
3.1.2 Previously isolated compounds from Sargassum species 
Sargassum species are known to produce secondary metabolites of structural classes such as 
plastoquinones, chromanols, chromenes, steroids and glycerides (Reddy 2009). From these 
structural classes, much interest has been focused on the isolation of prenylated compounds 
due to their potential to possess a wide variety of biological activities. These hydroquinone 
and quinone moieties are derived from shikimic acid while their prenylated side chains may 
be derived from either the mevalonate (MVA) or the non-mevalonate (MEP) biosynthetic 
pathway (Eisenreich et al. 2004). 
Examples of biologically active prenylated compounds derived from the Sargassum genera 
(Figure 3.1) include anticholinesterase plastoquinones such as sargaquinoic acid (3.1) isolated 
from S. sagamianum (Choi et al. 2007), the endothelin inhibitor nahocol A (3.2) (a biogenetic 
precursor of ubiquitous prenyl-hydroquinones or benzoquinones) isolated from S. autumnale 
(Tsuchiya et al. 1998), the bone resorption inhibitory activity and antiviral activity (against 
human cytomegalovirus) of the meroditerpenoids 14′,15′-dihydroxysargahydroquinone (3.3) 
and 11′,12′-dihydro-11′,12′-dihydroxysargaol (3.4) isolated from S. micracanthum (Komai et 
al. 2006) and the potential PPAR-γ transactivation activity of plastoquinones such as 
meroterphenol C (3.5) isolated from Korean S. yezoense (Kim et al. 2011). Research has also 
shown that most of these prenylated compounds possess anti-oxidant properties with the 
hydroquinones being more potent than their corresponding quinones. 
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Figure 3.1 Prenylated compounds isolated from the Sargassum genera possessing various 
biological activities. 
3.1.3 Bioactive compounds isolated from S. heterophyllum 
Prenylated toluquinols isolated from S. heterophyllum have been reported to have 
antiplasmodial activity. Afolayan et al. (2008) screened 22 marine algae, of which the S. 
heterophyllum extract showed the most promising antiplasmodial activity (Afolayan et al. 
2008). The tetraprenyl toluquinol sargaquinal (3.7) and the carotenoid all-tans-fucoxanthin 
(3.8) both showed good antiplasmodial activity towards a chloroquine sensitive P. falciparum 
D10 strain. The S. heterophyllum metabolites sargahydroquinoic acid (3.6) and sargaquinoic 
acid (3.1) have both been reported as dual agonists for PPARα/γ (Kim et al. 2008). 
Sargachromenoic acid (3.9), a metabolite from S. heterophyllum (Munedzimwe 2012), has 
been reported to potentiate nerve growth factor (NGF) mediated neurogenesis and is 
therefore, a potential neuroprotective agent for the prevention of progressive neuronal death 
characteristic of neurodegenerative diseases (Tsang et al. 2005). 
3.1.4 Chapter aims 
In Chapter 2, after screening several algae, we discovered that crude extracts obtained from S. 
heterophyllum exhibited the most potent anti-oxidant and anti-inflammatory activity. In this 
Chapter, we describe the isolation and characterization of pure natural products from S. 
heterophyllum as well as the preparation of a series of synthetic derivatives for further 
pharmacological studies. 
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3.2 Results and Discussion 
3.2.1 Extraction and isolation of metabolites from Sargassum heterophyllum 
Specimens of S. heterophyllum (NDK101124) were collected on the 24
th
 of November, 2010 
from Noordhoek, Port Elizabeth on the southeast coast of South Africa. The alga was first 
extracted with MeOH followed by CH2Cl2/MeOH (2:1). Extracts were combined and 
sufficient deionised water was added to allow separation of the aqueous MeOH and CH2Cl2 
phases. A dark green oil (MN-11-62) was obtained after concentration of the CH2Cl2 phase 
under rotary evaporation.  The 
1
H NMR spectrum of the crude extract (Figure 3.2) exhibited 
two singlets at δ 6.46 and 6.48, and a doublet at δ 3.28. These signals are characteristic of 
prenylated hydroquinones/quinones previously isolated from this alga (Afolayan et al. 2008) 
and are likely to be responsible for its anti-oxidant activity. 
 
Figure 3.2 
1
H NMR spectrum (CDCl3, 400MHz) of S. heterophyllum crude extract 
The red arrows indicate signals characteristic of prenylated quinones/hydroquinones 
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Fractionation of the crude extract by silica gel column chromatography using a step-gradient 
of increasing polarity (hexane-EtOAc-MeOH) yielded nine crude fractions (64a-i).  Further 
purification, by either silica column chromatography or HPLC, was guided by DPPH free 
radical scavenging activity and 
1
H NMR spectroscopy (Scheme 3.1, Figure 3.3) to yield 
compounds 3.6, 3.7 and 3.8. 
 
 
S. heterophyllum
Seaweed
MeOH @40 oC for 1 hr
Aq/MeOH
CH2Cl2 Extract
CH2Cl2/MeOH (2:1)         2X
Aq/MeOH Extract
Fr 64a
17.2 mg
i
Fr 64b
20.7 mg
Fr 64c
143.1 mg
Fr 64d
3.6
284.5 mg
Fr 64e
32.6 mg
Fr 64f
3.8
35.5 mg
Fr 64g
6.6 mg
Fr 74j
3.7
3.0 mg
Fr 64h
2.5 mg
iv
iiiii
 
Scheme 3.1  Isolation of compounds 3.6, 3.7, and 3.8 from S. heterophyllum 
Conditions: (i) Silica gel column chromatography of MN-11-62, mobile phase hexane-
EtOAc. (ii) Silica gel column fraction, hexane-EtOAc (7:3). (iii) Silica gel column fraction, 
hexane-EtOAc (4:6). (iv) Normal Phase HPLC fraction, hexane-EtOAc (9:1) 
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Figure 3.3 
1
H NMR spectra (CDCl3, 400 MHz) of S. heterophyllum silica gel column 
fractions 64a-i 
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3.2.2 Structural characterization of isolated compounds 
3.2.2.1 Characterization of compound 3.6 
Compound 3.6 was the major compound isolated from the crude extract. It’s 1H NMR 
spectrum showed key signals in the aromatic region at δ 6.46 and 6.50 and a methylene 
doublet at δ 3.29.  The 13C NMR spectrum of compound 3.6 showed 27 carbon resonances, 
including a carbonyl signal at δ 172.7 characteristic of a carboxylic acid functional group. 
Comparison of 
1
H and 
13
C NMR spectroscopic data with that found in literature for 
metabolites previously isolated from S. heterophyllum confirmed that compound 3.6 was 
sargahydroquinoic acid (SHQA) (Munedzimwe 2012). This compound has been previously 
isolated from several Sargassum species including S. heterophyllum (Afolayan et al. 2008), S. 
yezoense (Kim et al. 2011), and S. thunbergii (Seo et al. 2006). The trace impurity at δ 2.17 is 
residual acetone. 
CDCl3
H-3, 5
H-2′
H-1′
H-9′
1'
2' 6' 10'
19'20'
35
7
3.6
14'
17'
16'
H-10′
H-6′, 14′
 
Figure 3.4 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.6 
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Figure 3.5 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.6 
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3.2.2.2 Characterization of compound 3.7 
Compound 3.7 was isolated from fraction 64b (Figure 3.3) and its 
1
H NMR spectrum (Figure 
3.6) showed a sharp aldehyde singlet at δ 9.34. The latter showed an HSQC correlation to a 
carbon signal at δ 195.2 which, combined with the loss of the carboxylic acid carbon signal at 
 172.7 (in 3.6) confirmed the presence of an aldehyde moiety. Furthermore, the 13C NMR 
spectrum of compound 3.7 (Figure 3.6) also showed the presence of a benzoquinone carbonyl 
at δ 188.3. Comparison of 1H NMR and 13C NMR spectroscopic data with those found in 
literature helped us to identify compound 3.7 as 2′E,6′E,10′E- sargaquinal and not 
2′E,6′E,10′Z- sargaquinal. 
CDCl3
H-18′ H-3, 5, 10′
H-2′ H-1′
35
7
2' 6' 10'
18'
17'
19'20'
3.7
 
Figure 3.6 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.7 
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Figure 3.7 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.7 
Compound 3.7 has been previously isolated from several Sargassum species including S. 
serratifolium (Kusumi et al. 1979) and S. heterophyllum (Afolayan et al. 2008) whereas its 
isomer has been successfully synthesized from sargaquinoic acid (compound 3.1) (Kusumi et 
al. 1979). 
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Table 3.1  
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data 
for compounds 3.6 and 3.7  
                 3.6                 3.7 
 
Carbon No. 
δC δH 
mult, JHz 
δC δH 
 mult, JHz 
1 146.2  188.3  
2 125.5  146.2  
3 115.4 6.5, br s 132.4 6.55, br s 
4 148.9  187.9  
5 114.1 6.46, br s 132.4 6.44, m 
6 127.7  148.4  
7 16.1 2.17, s 16.0 2.06, m 
1′ 29.9 3.29, d, 6.90 27.5 3.12, d, 6.8 
2′ 121.8 5.27, t, 118.1 5.15, m 
3′ 138  139.7  
4′ 39.4 2.08, m 39.5 2.06, m 
5′ 26.0 2.11, m 26.3 2.09, m 
6′ 124.2 5.10, d, 6.70 125.1 5.11, m 
7′ 134.7  133.9  
8′ 39.0 2.07, m 38.3 2.15, m 
9′ 28.3 2.58, q, 7.5 27.0 2.44, q, 7.6 
10′ 145.1 6.00, t, 7.2 155.1 6.42, m 
11′ 130.7  143.1  
12′ 34.6 2.26, t, 7.6 27.5 2.26, t, 8.0 
13′ 27.8 2.11, m 25.7 2.15, m 
14′ 123.5 5.09, d, 7.2 123.5 5.15, m 
15′ 132.2  133.1  
16′ 25.6 1.68, s 24.2 1.66, s 
17′ 17.7 1.58, s 17.7 1.56, br s 
18′ 172.7  195.2 9.34, s 
19′ 16.0 1.59, br s 16.0 1.63, s 
20′ 16.1 1.75, s 16.1 1.62, s 
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3.2.2.3 Characterization of compound 3.8 
The 
1
H and 
13
C NMR spectra of compound 3.8 (Figures 3.8, 3.9 and Table 3.2) showed no 
resemblance to those of compounds 3.6 and 3.7 with a total of 42 resonances in the 
13
C NMR 
spectrum mostly observed in the olefinic region (δ 100 and 150) and several overlapping 
peaks on the 
1
H NMR spectrum (Figure 3.8). Upon isolation, compound 3.8 had a strong red-
orange colour that suggested the presence of conjugated double bonds characteristic of 
carotenoid compounds as an attribute of conjugated pi systems that are able to absorb light of 
lower energy levels and reflect the complimentary colours. Comparison of the 
1
H and 
13
C 
NMR spectroscopic data with known carotenoids isolated from S. heterophyllum (Afolayan et 
al. 2008) allowed for the identification of compound 3.8 as fucoxanthin. 
 
3.8 19'
9'
15' 11'
1' 3'
16'
17'
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1
3
20
20'
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11
CDCl3
 
Figure 3.8 
1
H NMR spectrum (CDCl3, 400 MHz) of compound 3.8 
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Figure 3.9 
13
C NMR spectrum (CDCl3, 100 MHz) of compound 3.8  
 
Table 3.2 
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data 
for compound 3.8 
Carbon 
No. 
δC δH 
mult, JHz 
Carbon 
No. 
δC δH 
 mult, 
JHz 
1 35.72  11 123.4 6.54 
1′ 35.12  11′ 125.65 6.58 
2 47.0  12 145.1 6.66 
2′ 45.40 1.48 12′ 137.1 6.33 
3 64.3 3.82 13 135.4  
3′ 8.1 5.37 13′ 138.04  
4 41.50 1.74 14 136.6 6.39 
4′ 45.20 1.51 14′ 132.13 6.25 
5 66.23  15 129.37 6.63 
5′ 72.66  15′ 132.48 6.75 
6 67.16  16 25.00 1.03 
6′ 117.4  16′ 21.37 1.81 
7 40.74 2.58, 3.641 17 28.10 0.96 
7′ 202.35 3.63 17′ 32.04 1.07 
8 197.9  18 21.10 1.22 
8′ 103.34 6.05 18′ 31.20 1.35 
9 134.43  19 11.80 1.94 
9′ 132.5  19′ 13.97 1.81 
10 139.2 7.13 20 12.71 1.99 
10′ 128.5 6.11 20′ 12.87 1.99 
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3.2.3 Synthesis of sargahydroquinoic acid derivatives 
Although sargaquinoic acid (SQA, 3.1) and sargachromenoic acid (3.9) have been isolated 
from S. heterophyllum in minute quantities (Munedzimwe 2012), we decided to synthesize 
these compounds from sargahydroquinoic acid (SHQA, 3.6), which could be isolated in gram 
quantities from the alga. 
 
 
 
Sargaquinoic acid (3.1) has been previously isolated from S. heterophyllum (Afolayan et al. 
2008) and has been synthesized by the oxidation of SHQA using MnO2 and Ag2O 
(Munedzimwe 2012). Thus, the oxidation of SHQA (3.6) with Ag2O gave SQA (3.1) in 65.1 
% yield (Scheme 3.2). Not surprisingly, the major differences in the 
1
H NMR spectra of the 
two compounds were due to the signals of H-3, H-5 and H-1′. These protons resonate at δ 
6.50, 6.46 and 3.29, respectively, in SHQA (Figure 3.10 and Table 3.1) and at δ 6.56, 6.47 
and 3.12, respectively, in SQA (Figure 3.10 and Table 3.3). The 
13
C NMR spectrum of SQA 
clearly shows carbon signals at δ 187.9 and 188.0 due to the presence of the quinone moiety. 
(65.1 %)
R=
(4.38 %)
(43.1 %)
Ag
2
O
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Scheme 3.2 Synthesis of sargaquinoic acid (3.1), sargachromenoic acid (3.9) and 
sarganaphthoquinoic acid (3.10) 
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Figure 3.10 
1
H NMR spectra (CDCl3, 400 MHz) of compounds 3.1, 3.6, 3.9 and 3.10 
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Sargachromenoic acid (3.9) has been reported from S. fallax (Reddy and Urban 2009) as well 
as from S. serratifolium (Kusumi et al. 1979). The synthetic transformation of hydroquinones 
into quinones with subsequent conversion to chromenols has been reported (Kusumi et al. 
1979;Pérez-Castorena et al. 2002). It has also been suggested that this conversion occurs 
from hydroquinones directly to chromenols by cyclization between the hydroxyl of the 
hydroquinone and the C-3
′ 
of the polyprenylated side chain (Scheepers 2006). In our hands, 
the treatment of SQA with pyridine at room temperature gave sargachromenoic acid (3.9) in 
almost quantitative yields. A tautomerism/electrocyclization mechanism has been proposed 
for the formation of chromenes from quinones (Scheme 3.3). 
-
3.1
3.9  
Scheme 3.3 Proposed mechanism for the synthetic conversion of sargaquinoic acid (3.1) to 
sargachromenoic acid (3.9) (Lumb et al. 2008) 
The most diagnostic feature of the 
1
H NMR spectrum of compound 3.9 (Figure 3.10) was the 
two mutually coupled olefinic protons at δ 6.26 and 5.58. In addition, signals due to the 
protons H-3 and H-5 had shifted from δ 6.53 and 6.45 in SQA to 6.32 and 6.47 in 3.9. 
Comparison of 
1
H and 
13
C NMR spectroscopic data with that found in literature 
(Munedzimwe 2012) confirmed the identification of compound 3.9 as sargachromenoic acid. 
Munedzimwe (2012) previously reported the isolation of compound 3.10 as a minor side 
product during the Ag2O catalyzed oxidation of SHQA to SQA (Munedzimwe 2012). A 
related compound, chabrolonaphthoquinone A, was previously isolated from the soft coral 
Nephthea chabrolii differing by the geometry of the ∆10-11 double bonds and the positioning 
of the methyl substituent at C-5′ rather than C-6′ (Sheu et al. 2004). Scheme 3.4 shows a 
proposed biosynthetic pathway by Sheu et al. in which oxidation of SHQA at C-20 forms an 
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intermediate which is subsequently alkylated and oxidized to form compound 3.10. The 
proposed mechanism for the synthesis of compound 3.10 from SQA includes the oxidation of 
SHQA to SQA followed by tautomerism to intermediate A which, after oxidation to the 
quinone is able to undergo a Diels-Alder reaction to intermediate B which after further 
oxidation gives the naphthoquinoic acid (Scheme 3.5). Considering the proposed mechanism, 
we reasoned that addition of a base subsequent to the oxidation of SHQA to SQA should 
facilitate the formation of 3.10. The reaction of SHQA with six equivalents of Ag2O for 24 h 
followed by three drops of triethylamine and stirring at room temperature for a further 24 h 
gave 3.10 in 43.1 % yield after purification. 
3.6
3.10
a
b
a
 
Scheme 3.4 Proposed biosynthetic pathway for sarganaphthoquinoic acid (4.2) from 
sargahydroquinoic acid (3.6). (a) Oxidation, (b) Friedel-Craft’s alkylation 
(Sheu et al. 2004) 
From the 
1
H
 
NMR spectrum of compound 3.10 (Figure 3.11), the upfield signals at  7.52, 
7.86 and 8.00 are typical of the naphthoquinone system. In addition, one of the aromatic 
singlets shifted downfield from  6.46 in SHQA to 6.81. Comparison of 1H and 13C NMR 
spectroscopic data with that found in literature (Munedzimwe 2012) confirmed the 
identification of compound 3.10 as sarganaphthoquinoic acid. 
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sargahydroquinoic acid (3.6)
sarganaphthoquinoic acid (3.10)
A
I
B
II
I II
III
Diels-Alder Product
I
sargaquinoic acid (3.1)
 
Scheme 3.5 Proposed mechanism for the synthetic conversion of sargahydroquinoic acid 
(3.6) to sarganaphthoquinoic acid (3.10) 
(I) Oxidation. (II) Tautomerism. (III) Diels-Alder reaction. 
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Table 3.3 
1
H (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100 MHz) spectroscopic data for 
compounds 3.1 and 3.9 
             3.1              3.9 
 
Carbon No. 
δC δH 
mult, JHz 
δC δH 
 mult, JHz 
1 188.0  145.8  
2 145.9  121.1  
3 133.1 6.53, s 110.4 6.32, d, 2.5 
4 187.9  148.5  
5 132.2 6.45, s 117.2 6.47, d, 2.4 
6 148.5  126.0  
7 177.7 2.08, m 15.7 2.13, s 
1′ 27.5 3.12, d, 7.3 122.9 6.26, s 
2′ 117.9 5.11, dt 130.7 5.58, d, 9.8 
3′ 139.8  77.7  
4′ 39.6 2.08, m 40.8 1.67, s 
5′ 26.3 2.10, m 22.8 2.05, m 
6′ 124.5 5.11, m 124.9 5.12, dt, 19, 6.4 
7′ 134.6  134.1  
8′ 39.0 2.10, m 39.3 2.06, m 
9′ 28.2 2.58, q, 7.5 28.1 2.59, q, 7.3 
10′ 145.4 6.00, t, 7.0 144.5 5.98, t, 7.3 
11′ 130.6  130.4  
12′ 34.5 2.25, t, 7.7 34.9 2.25, t, 7.4 
13′ 27.9 2.10, m 28.1 2.13, s 
14′ 123.4 5.11, m 123.3 5.12, dt, 19, 6.4 
15′ 132.2  132.3  
16′ 25.6 1.66, s 25.7 1.67, s 
17′ 16.1 1.59, s 17.9 1.57, s 
18′ 172.7  172.2  
19′ 16.0 1.60, s 15.6 1.57, s 
20′ 16.1 1.61, s 25.9 1.68, s 
 
In this Chapter, we managed to isolate and characterize the pure natural products 
sargahydroquinoic acid (3.6), E-sargaquinal (3.7) and fucoxanthin (3.8) from S. 
heterophyllum. From sargahydroquinoic acid (3.6), we then prepared the synthetic derivatives 
sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10) for 
further pharmacological studies. 
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3.3 Experimental 
3.3.1 General experimental procedures 
All extractions and chromatography utilised HPLC grade solvents supplied by Lichrosolv
®
 
(Merck, Germany). NMR experiments were obtained on a Bruker Avance 400 MHz NMR 
spectrometer using standard pulse sequences. All HPLC solvents were filtered through a 0.45 
m filter before use. Normal phase HPLC was performed using a Spectra-Physics IsoChrom 
pump, Whatman
®
 Partisil 10 (9.5 mm × 500 mm) semi-preparative column and a Waters 410 
differential refractometer attached to a 100 mV full scale Rikadenki chart recorder. 
3.3.2 Algal Material 
The algal specimen of S. heterophyllum (NDK101124) was collected from Noordhoek, near 
Port Elizabeth, on the southeast coast of South Africa on the 24
th
 of November 2010. The 
algal specimens were transported to the laboratory on ice where it was immediately frozen 
and stored until the time of extraction. For purposes of identification and authentication the 
algal material was morphologically compared with previous voucher specimens of S. 
heterophyllum.  A voucher specimen is kept at the Division of Pharmaceutical Chemistry, 
Rhodes University, Grahamstown, South Africa. 
3.3.3 Extraction and Isolation of metabolites 
Frozen algal material (NDK101124) was allowed to defrost under running distilled water. 
Defrosted algae were then soaked in MeOH for 1 h after which the MeOH was decanted and 
the retained algae heated at 40 
o
C for 30 min in CH2Cl2/MeOH (2:1, 150 mL x3). MeOH and 
CH2Cl2/MeOH (2:1) mixtures were pooled and sufficient water added to allow for the 
separation of the CH2Cl2 and the MeOH/H2O phases. CH2Cl2 phase was then collected and 
dried in vacuo to yield the desired crude extract (MN-11-62, 12.4g). A portion of the crude 
extract (0.95 g) was applied to a silica gel column (10 g) and the column eluted using a series 
of solvents (50 mL each) of increasing polarity. This yielded the following fractions: 64a 
(hexane-EtOAc, 10:0, 17.2 mg), 64b (hexane-EtOAc, 9:1, 20.7 mg), 64c (hexane-EtOAc, 
8:2, 143.1 mg), 64d (hexane-EtOAc, 7:3, compound 3.6, 284.5 mg), 64e (hexane-EtOAc, 6:4, 
32.6 mg), 64f (hexane-EtOAc, 4:6, compound 3.8, 35.5 mg), 64g (hexane-EtOAc, 2:8, 6.6 
mg), 64h (EtOAc, 2.5 mg) and 64i (MeOH-EtOAc, 1:1, 207.7 mg). Fractions 64d and 64f 
contained pure sargahydroquinoic acid (3.6, 284.5 mg, 30% extracted yield) and fucoxanthin 
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(3.8, 35.5 mg, 3.74% extracted yield) respectively. Normal phase HPLC of fraction 64b (20.7 
mg) yielded compound 3.7 (3.0 mg, 15.4% dry weight). 
Sargahydroquinoic acid (3.6) 
Dark-green gum; 
1
H NMR data (CDCl3, 400 MHz) see Table 3.1; 
13
C NMR data (CDCl3, 100 
MHz) see Table 3.1. 
E-Sargaquinal (3.7) 
Orange-yellow oil; 
1
H NMR data (CDCl3, 400 MHz) see Table 3.1; 
13
C NMR data (CDCl3, 
100 MHz) see Table 3.1. 
Fucoxanthin (3.8) 
Red-orange oil; 
1
H NMR data (CDCl3, 400 MHz) see Table 3.2; 
13
C NMR data (CDCl3, 100 
MHz) see Table 3.2. 
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3.3.4 Semi-synthesis of derivatives 
3.3.4.1 Oxidation of sargahydroquinonic acid (3.6) to sargaquinoic acid (3.1) 
To a solution of sargahydroquinoic acid (165.8 mg) in CHCl3 (8 mL) and MeOH (7 mL) was 
added Ag2O (100 mg) and the resulting mixture was stirred at room temperature for 24 h.  
The mixture was filtered through a column of activated charcoal and passed through a plug of 
silica gel (hexane-EtOAc, 4:6, 10 mL) to yield sargaquinoic acid (3.1, 108 mg, 65.1 % dry 
weight) as a yellow compound after concentration under reduced pressure. All spectroscopic 
data for 3.1 are consistent with those previously reported (Afolayan et al. 2008;Munedzimwe 
2012). 
Sargaquinoic acid (3.1) 
Yellow oil (65.1%); 
1
H NMR data (CDCl3, 400 MHz) see Table 3.3; 
13
C NMR data (CDCl3, 
100 MHz) see Table 3.3. 
3.3.4.2 Conversion of sargaquinoic acid (3.1) to sargachromenoic acid (3.9) 
To sargaquinoic acid (56.1 mg) was added pyridine (3 mL) and stirred at room temperature 
for 15 h under nitrogen gas. The extract was solubilised in EtOAc (10 mL), acidified with 5M 
HCl and extracted 3 times, each time collecting the EtOAc layer. The EtOAc extract was then 
filtered through Na2S to yield sargachromenoic acid (3.9, 24.2 mg, 43.1 % dry weight) after 
concentration under reduced pressure. All spectroscopic data for 3.9 are consistent with those 
previously reported (Munedzimwe 2012). 
Sargachromenoic acid (3.9) 
Orange-yellow oil (43.1 %); 
1
H NMR data (CDCl3, 400 MHz) see Table 3.3; 
13
C NMR data 
(CDCl3, 100 MHz) see Table 3.3. 
3.3.4.3 Conversion of sargahydroquinoic (3.6) acid to sarganaphthoquinone (3.10) 
To a solution of sargahydroquinoic acid (111.9 mg) in EtOH (15 mL) was added six 
equivalents of Ag2O (326 mg) and stirred at room temperature for 24 h. To the reaction 
mixture was then added 3 drops of triethylamine (TEA) and further stirred for another 24 h. 
The resulting crude extract was filtered through a 5 g silica column (hexane-EtOAc, 7:3, 2 
mL) to yield  sarganaphthoquinoic acid (3.10, 4.9 mg, 4.38% dry weight) after concentration 
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under reduced pressure. All spectroscopic data for 3.10 are consistent with those previously 
reported (Munedzimwe 2012). 
Sarganaphthoquinoic acid (3.10) 
Orange-yellow oil (4.38%); 
1
H NMR (400 MHz, CDCl3) δ 8.01 (d, J=7.9 Hz), 7.86 (s), 7.52 
(dd, J=7.9 Hz), 6.81 (s), 5.97 (t, J=7.3 Hz), 5.16 (t, J=7.0 Hz), 2.78 (t, J=7.6 Hz), 2.59-2.55 
(m), 2.36-2.32 (m), 2.25 (m), 2.18 (s), 2.13-2.12 (m), 2.05-2.02 (m), 1.67 (s), 1.58 (s). 
13
C NMR (100 MHz, CDCl3) δ 185.44, 185.41, 171.9, 149, 148.2, 145, 136, 136, 136, 133.8, 
132.3, 132.2, 130.6, 130.2, 126.7, 125.9, 123.4, 123.2, 39.01, 36.17, 29.1, 28.19, 28.19, 
25.63, 17.65, 16.44, 15.94. 
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Chapter 4 
In-vitro anti-diabetic (insulinomimetic) activity of sargahydroquinoic acid 
semi-synthetic derivatives 
4.1 Introduction 
In Chapter 3, we identified the main metabolite obtained from the dichloromethane crude 
extract of S. heterophyllum as sargahydroquinoic acid (SHQA, 3.6) from which sargaquinoic 
acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10) were synthesized. 
Other compounds isolated from the dichloromethane crude extract of S. heterophyllum 
included E-sargaquinal (3.7) and fucoxanthin (3.8). However, the vulnerability of aldehyde 
compounds such as 3.7 to nucleophilic attack at the carbonyl carbon and hence, their high 
reactivity in biological systems gave reason to avoid the inclusion of this compound in our in-
vitro anti-diabetic studies. With much research of this nature already done on fucoxanthin 
(3.8), this chapter only seeks to investigate the potential anti-diabetic activity of SHQA and 
its semi-synthetic derivatives (compounds 3.1, 3.9 and 3.10). 
4.1.1 Mechanistic selection of an in-vitro anti-diabetic model 
The potential anti-diabetic activity of a compound or extract may be assessed clinically using 
human subjects, in-vivo using animal models or in-vitro using a variety of test experiments. 
While each level of assessment has merits and demerits, the role of in-vitro models as an 
initial screening tool is significant in the determination of the anti-diabetic activity of test 
compounds or extracts (Soumyanath and Srijayanta 2006). By having a controlled system 
within which experimental variables of a test compound can be measured, in-vitro models 
enable the study of biological mechanisms of action as a scientific advantage over in-vivo 
models in addition to ethical and cost advantages (Sceats 2010). Several existing in-vitro anti-
diabetic models are employed either for random screening or for the determination of the 
mechanisms of action of compounds and extracts. Since diabetes is a heterogeneous group of 
disorders characterized by a variety of pathogenic abnormalities, it offers numerous 
therapeutic targets that can be exploited in the quest of finding new treatment options. The 
four anti-diabetic mechanisms of action or therapeutic targets mainly tested for are; inhibition 
of carbohydrate digestive enzymes, the impairment of glucose uptake from the small 
intestinal lumen, stimulation of β-pancreatic insulin release, insulinomimetic or insulin-
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sensitizing activity at insulin target tissues (e.g. liver, skeletal muscle and adipocytes) and 
antagonism of glucagon activity (Soumyanath and Srijayanta 2006). 
Currently used in-vitro anti-diabetic assays incorporate most of these therapeutic targets. 
However, it is important to note that these in-vitro assays do not represent a comprehensive 
anti-diabetic screening system and that compounds or extracts that show lack of anti-diabetic 
activity on one particular therapeutic target may show positive results on another target. 
Therefore, with these limitations associated with in-vitro assays, there is no guarantee to 
ascertain anti-diabetic activity in in-vivo models post in-vitro studies. Hence, results obtained 
from in-vitro studies should be considered as an initial screening process for the identification 
of compounds or extracts with specific anti-diabetic mechanisms which then need to be 
followed by bioassay guided fractionation in the case of extracts and in-vivo anti-diabetic 
models. In addition to direct anti-diabetic therapeutic targets, other secondary anti-diabetic 
properties such as anti-oxidant and anti-inflammatory activity as well as cytotoxicity profiles 
need to be considered. 
4.1.1.1 Adipocytes as an insulin target tissue 
Once thought only as a storage organ for triacylglycerol, the development and biochemistry 
of adipose tissue has substantially gained interest and intrigued research for decades. The 
adipocyte has been described as “a dynamic cell that plays a fundamental role in energy 
balance and overall body homeostasis” (Bernlohr et al. 2002). In humans, the adipose organ 
consists of brown adipose tissue (BAT) and white adipose tissue (WAT) (Farmer 2008). Of 
the two, WAT is the most predominant and functions as an energy store in the form of 
triglyceride-containing intracellular droplets. The WAT also secretes a wide range of 
hormones and ‘adipocytokines’ which affect the functioning of various tissues such as the 
brain, muscles, and the liver (Gesta et al. 2007). However, since these ‘adipocytokines’ are 
mostly neither ‘cytokines’ nor ‘cytokine-like’, suggestions have been made for the adoption 
of the term ‘adipokine’ to describe a protein that is secreted from and synthesized by 
adipocytes (Trayhurn and Wood 2004). The adipokines are normally divided into pro-
inflammatory and anti-inflammatory. The monocyte chemoattractant protein-1 (MCP-1), 
tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) are examples of pro-inflammatory 
adipokines while adiponectin is an example of anti-inflammatory adipokine (Trayhurn and 
Wood 2004). The BAT are mainly specialized for thermogenesis, which is heat generated via 
the accelerated oxidation of triacylglycerides within brown adipocytes facilitated by large 
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numbers of mitochondria. The BAT also exclusively expresses uncoupling protein-1 (UCP-
1), a proton transporter that uncouples electron transport from ATP production and allows the 
energy to be dissipated as heat (Farmer 2008;Ricquier and Bouillaud 2000). The induced up-
regulation of mitochondrial activity and acquired BAT-like properties such as the expression 
of UCP-1 in WAT (Toh et al. 2008) has formed the basis for using adipocytes as an anti-
obesity therapeutic target. The carotenoid fucoxanthin has been reported to have anti-obesity 
effects through this particular mechanism of action (Maeda et al. 2005). 
The formation of adipocytes (adipogenesis) is a differentiation process governed by 
transcriptional cascades involving a regulated set of gene expression events. The peroxisome 
proliferator activated receptor γ (PPARγ) has been termed by Rosen and MacDougald as “the 
‘master regulator’ of adipogenesis” (Rosen and MacDougald 2006). The PPARγ is sufficient 
to differentiate fibroblasts into mature adipocytes without which no other factor has yet been 
realised (Rosen and MacDougald 2006). The PPARγ is therefore not only crucial for 
adipogenesis but is also a requirement for the maintenance of the differentiated state (Rosen 
and MacDougald 2006). Hence, a compound or extract that stimulates the differentiation of 
preadipocytes into mature adipocytes is most likely a PPARγ agonist. The PPARγ is 
predominately expressed in adipose tissue with lower levels of expression in other tissues 
such as cardiac, renal and hepatic tissues (Shearer and Billin 2007). The association of 
PPARγ activation and consequent adipogenesis with an increase in tissue insulin sensitivity 
provided the basis for the development of TZD’s as a class of anti-diabetic drugs (see 
Chapter 1, Section 1.6.1.5). 
4.1.1.2 Sargahydroquinoic acid and sargaquinoic acid as potential PPARα/γ agonists 
PPARγ agonists (TZD’s) are a potentially ideal class of anti-diabetic agents in the prevention 
of diabetic cardiovascular complications. However, current TZD’s are associated with weight 
gain, fluid accumulation, pulmonary oedema and macular oedema which ultimately results in 
congestive heart failure (Shearer and Billin 2007). Since PPARα agonists have been used to 
treat dyslipidemia via their effects on lowering free triglyceride concentrations in plasma, 
PPARγ side effects may be circumvented by the combined activation of PPARα/γ which 
should result in a synergistic enhancement of lipid metabolism and insulin sensitivity (Kim et 
al. 2008). Because of this, several attempts have been made to develop PPARα/γ dual 
agonists. 
 
82 
 
According to a study performed by Kim et al., Sargahydroquinoic acid (3.6) and its quinone 
congener sargaquinoic acid (3.1) both isolated from S. yezoense were reported to be dual 
agonists for PPARα/γ by increasing receptor transcriptional activity (Kim et al. 2008). The 
development of several PPARα/γ agonists including muraglitazar, tesaglitazar and 
ragaglitazar has been discontinued due to adverse effects such as oedema, heart failure, renal 
dysfunction and carcinogenesis (Shearer and Billin 2007). This is because a balance in the 
binding affinity of PPARα/γ dual agonists towards both receptor subtypes is required for 
optimal biological activity such that supra therapeutic activation of either PPARα or PPARγ 
results in adverse effects. Therefore, there is need for the development of new PPARα/γ 
selective agonists with balanced activity. In the study performed by Kim et al., the PPARα 
activation of SHQA was higher (4.3-fold) than that on PPARγ (2.1-fold) while SQA had a 
more balanced activation on PPARα and PPARγ (2.6-fold and 3.0-fold respectively) (Kim et 
al. 2008). Considering that the potential anti-diabetic mechanism of action of SHQA (3.6) 
and possibly its derivatives may be via the PPARγ which is predominantly expressed in 
adipose tissue, we decided to use adipocytes as the therapeutic target tissue through the 3T3-
L1 preadipocyte differentiation assay. 
4.1.1.3 The 3T3-L1 preadipocyte differentiation 
The adipocytes are highly sensitive to insulin and hence, act as a target site for the study of 
insulinomimetic or insulin sensitizing activity. Insulin in adipocytes causes glucose uptake 
(controlled by the GLUT4 glucose transporter), lipogenesis and inhibition of triglyceride 
hydrolysis. The differentiation of preadipocytes into primary adipocytes, glucose uptake, 
lipogenesis and inhibition of lipolysis in differentiated cells are all insulinomimetic effects 
(Soumyanath and Srijayanta 2006). The 3T3-L1 is a preadipocyte cell line that was originally 
developed by clonal expansion from murine Swiss 3T3 cells (Zebisch et al. 2012). The ability 
of the 3T3-L1 preadipocytes to differentiate from fibroblasts to adipocytes makes them 
suitable as an anti-diabetic model for the observation of insulinomimetic effects. For the 
transformation of 3T3-L1 fibroblasts into mature adipocytes, the cells are normally treated 
post-confluence with either a combination of recombinant insulin (1 μg/mL), dexamethasone 
(DEX, 0.25 μM), and 3-isobutyl-1-methylxanthine (IBMX, 0.5 mM) or a PPARγ agonist 
such as rosiglitazone (Zebisch et al. 2012). 
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Figure 4.1 Schematic overview of the sequential steps involved in the 3T3-L1 
differentiation process 
In-vitro cultured proliferating 3T3-L1 preadipocytes cells contain high levels of 
retinoblastoma protein (Rb) in phosphorylated early gene 2 factor (E2F) -nonbinding form 
which is required for the transcription of the S phase genes (Figure 4.1). As cells progress 
towards contact inhibition and consequent growth arrest, the level of phosphorylated Rb 
decreases resulting in enhanced pRb-E2F complex formation and growth arrest at G1 phase 
(Johnson 2005). Only once preadipocytes become growth arrested can they be induced to 
differentiate. Activated transcription factor CCAAT/enhancer binding protein β (C/EBPβ) 
and activated transcription factor CCAAT/enhancer binding protein δ (C/EBPδ) are the first 
transcription factors to be induced after the exposure of preadipocytes to differentiating 
agents with C/EBPβ primarily responsive due to DEX (Ntambi and Young-Cheul 2000). 
Upon induction, the levels of C/EBPβ rapidly increase and growth arrested preadipocytes 
undergo mitotic clonal expansion involving two cycles of cell division. C/EBPβ in turn 
regulates the expression of the two major adipogenesis transcription factors, C/EBPα and 
PPARγ (Clarke et al. 1997), which together coordinate the dephosphorylation of Rb with 
subsequent growth arrest and the cessation of mitotic clonal expansion. Activated 
transcription factor CCAAT/enhancer binding protein α (C/EBPα) and PPARγ also promote 
the sustained expression of numerous adipocyte specific genes including GPDH which is 
required for the formation of triglyceride droplets (the main phenotypic feature of mature 
adipocytes). Both C/EBPα and PPARγ, the latter in combination with the obligate 
heterodimeric partner, the retinoid X receptor alpha (RXRα), have been shown to bind 
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regulatory elements within the promoter of the cytosolic glycerol-3-phosphate dehydrogenase 
(cytGPDH) gene. 
4.1.2 Chapter aims 
In Chapter 3, we managed to isolate and characterize pure natural products from crude 
fractions of S. heterophyllum and prepared a series of synthetic derivatives. In this chapter, 
we explore the potential anti-oxidant/radical scavenging activity, anti-inflammatory activity 
and cytotoxicity of S. heterophyllum fractions and pure natural products. Finally, we 
investigate and rationalize the potential anti-diabetic activity of SHQA and synthetic 
derivatives. 
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4.2 Results and Discussion 
4.2.1 DPPH anti-oxidant/radical scavenging Assays 
S. heterophyllum crude fractions were evaluated for DPPH radical scavenging activity using 
ascorbic acid as standard. Fractions 64c (mainly SQA, IC50 = 19.48 µg/mL), 64d (IC50 = 4.01 
µg/mL) and 64e (IC50 = 3.32 µg/mL) exhibited strong DPPH radical scavenging activity 
more potent than ascorbic acid (IC50 = 24.07 µg/mL) (Table 4.1). There should be 
background fucoxanthin absorbance in fraction 64f which would interfere with the DPPH 
quantification and as such, it was not possible to reliably determine its antioxidant activity 
under these experimental conditions. However, extensive research has already been 
undertaken to show among many others, the anti-oxidant, anti-inflammatory and anti-cancer 
activity of fucoxanthin (Peng Juan et al. 2011).  
 
Figure 4.2 Titration curves for DPPH anti-oxidant activity of fractions (64c), (64d) and (64c) 
Table 4.1 IC50 values for the DPPH radical scavenging activity of S. heterophyllum 
fractions 
Crude fraction IC50 (µg/mL) 
64a >500 
64b 113.9 
64c 19.48 
64d 4.01 
64e 3.32 
64g 43.14 
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The pure compounds SHQA (3.6), SQA (3.1), sargachromenoic acid (3.9), 
sarganaphthoquinoic acid (3.10) and a SQA/chlorophyll fraction (64c) were evaluated for 
DPPH anti-oxidant/radical scavenging activity also using ascorbic acid as standard (Table 
4.2). SHQA (3.6, IC50 = 6.20 µg/mL) and sargachromenoic acid (3.9, IC50 = 6.99 µg/mL) 
exhibited strong DPPH radical scavenging activity more potent than ascorbic acid (IC50 = 
24.07 µg/mL). The DPPH radical scavenging activity of SHQA and sargachromenoic acid 
has been previously documented (Pérez-Castorena et al. 2002).  It is a known fact that the 
reduced forms of vitamin E and coenzyme Q groups such as hydroquinones, chromanols and 
chromenols normally function as protective anti-oxidants. However, the ability of such 
compounds to function in these capacities of electron transfer and antioxidant activity directly 
depends upon the oxidation potential of the compound, which is also partly dependent upon 
the nuclear substituents (Moore et al. 1964). Not surprisingly, SHQA showed more potent 
DPPH radical scavenging activity than SQA (IC50 = 95.76 µg/mL) as it is generally known 
that hydroquinones are more potent radical scavengers than their quinone congeners. 
However, the SQA/chlorophyll fraction (64c) (IC50 = 19.48 µg/mL) possessed a more potent 
DPPH radical scavenging activity than SQA alone. This ‘synergism’ may have possibly 
resulted from the additive DPPH radical scavenging activity of chlorophyll which has been 
previously reported (Endo et al. 1985). Endo et al. proposed that the radical scavenging 
activity of chlorophyll involves a third order reaction in which electron donation from the π-
cation radical of the porphyrin and subsequent ‘molecular complexing’ results in free radical 
neutralization. 
3.6 3.9
 
Figure 4.3 Titration curves for DPPH radical scavenging activity of sargahydroquinoic 
acid (3.6) and sargachromenoic acid (3.9) 
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Table 4.2 IC50 values for the DPPH radical scavenging activity of sargahydroquinoic 
acid (3.6), sargaquinoic acid (3.1), sargachromenoic acid (3.9) and 
sarganaphthoquinoic acid (3.10) 
Compound IC50 (µg/mL) 
3.6 6.20 
3.1 95.76 
3.9 6.99 
3.10 226.5 
 
These results indicate that S. heterophyllum yields prenylated compounds with potent anti-
oxidant activity which may be exploited for therapeutic purposes. Since these results are 
based on in-vitro studies, further research is required in order to determine the biological 
relevance of DPPH radical scavenging capacity in in-vivo diabetic models. 
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4.2.2 Potential anti-inflammatory activity of S. heterophyllum fractions 
S. heterophyllum fractions were evaluated for anti-inflammatory activity. Fractions 64c 
(SQA/chlorophyll mixture), 64d (SHQA) and 64f (fucoxanthin) produced a significant 
decrease in nitrate production at both test concentrations, with fraction 64c being relatively 
less potent by only having a significant effect at the highest test concentration (Figure 4.4). 
The anti-inflammatory activity of fucoxanthin has been previously documented (Peng Juan et 
al. 2011). SHQA significantly attenuated nitrate production, indicating that this compound 
may also be considered to possess anti-inflammatory properties. A research on the anti-
inflammatory activity of plastoquinone derivatives isolated from natural sources also reported 
that SHQA significantly reduced TPA-induced mouse ear oedema (Pérez-Castorena et al. 
2002). Further research is however required to define the mechanism through which SHQA 
inhibits NO production and to assess the potential for synergism between fucoxanthin and 
SHQA. Under the conditions of the anti-inflammatory assay there was no evidence for 
cytotoxicity toward the RAW cells and thus, it can be assumed that the inhibition of nitrate 
production was not due to differences in the relative cytotoxicity. 
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Figure 4.4 Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions (64c), (64d), (64e) and (64f).
4
                                                          
4
 Data represents the mean ± STDev of four replicates from a single experiment. Significant (p<0.05) reductions in the levels of nitrate are indicated as (*) 
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4.2.3 Cytotoxicity assays for crude extracts and pure compounds 
Cytotoxicity towards Chang Liver, HT-29 and Caco-2 cell lines was evaluated for S. 
heterophyllum crude extracts. There appeared to be strong cytotoxicity of S. heterophyllum 
fractions on Chang Liver, HT-29 and Caco-2 cells (Table 4.3). This is consistent with studies 
that have been done to show the selectivity of Sargassum extracts towards HT-29 and Caco-2 
cell apoptosis (Khanavi Mahnaz et al. 2010). Fucoxanthin (64f), the most potent sample 
tested, was previously reported to inhibit the proliferation of HT-29 and Caco-2 cells through 
inducing cell cycle arrest in the Go/G1phase at low concentrations (25 μM) and apoptosis  at 
higher concentrations  (Das et al. 2005). Not surprisingly, the aldehyde mixture, 64b, was the 
second most cytotoxic fraction while fraction 64i was selective towards Chang Liver cells. 
Taken together these results indicate the presence of multiple cytotoxic compounds in the 
extracts of S. heterophyllum with potential anticancer properties. 
Table 4.3 EC50 values for S. heterophyllum fractions against Chang Liver, HT-29 and 
Caco-2 cells as obtained using the MTT assay.(nd = not determined) 
 
Fraction/ 
compound 
 
Sample purity 
 
EC50 Chang Liver 
(μg/mL) 
 
EC50 HT-29 
(μg/mL) 
 
EC50 Caco-2 
(μg/mL) 
α-tocopherol Pure  > 500 Nd Nd 
64a Crude fraction 39.55 150.2 126.8 
64b Sargaquinal Isomers 13.59 25.9 14.06 
64c SQA/chlorophyll 52.73 35.06 23.12 
64d Pure SHQA 82.2 114.8 58.25 
64e Crude fraction 266.4 369.5 146.1 
64f Pure fucoxanthin 12.11 19.83 14.82 
64g Crude fraction 32.46 116.5 117.6 
64h Crude fraction 75.05 Nd Nd 
64i Crude fraction 70.53 > 500 > 500 
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Cytotoxicity towards 3T3-L1 and Chang Liver cell lines was evaluated for SHQA (3.6), SQA 
(3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10). All the test 
compounds were more selective for 3T3-L1 than Chang Liver cells (Table 4.2) with the most 
selective being SHQA (SI = 7.9) and SQA (SI = 8.0). Literature has documented the selective 
cytotoxicity of SQA towards metastatic MDA-MB-231 breast cancer cells (Mare et al. 2012) 
as well as the human keratinocyte cell line HaCaT via apoptosis (Choi et al. 2007). The 
selective cytotoxicity of SHQA towards P338 cells has also been reported (Reddy and Urban 
2009). As we explained in Chapter 1, one of the main reasons for the assessment of the 
potential cytotoxicity of a test compound or extract prior to in-vitro anti-diabetic testing is to 
avoid the overriding of anti-diabetic endpoints by toxic effects which make the accurate 
assessment of anti-diabetic properties very difficult. Considering that a proliferatory phase is 
required for 3T3-L1 cells to differentiate, cytostatic or cytotoxic compounds often inhibit 
adipogenesis in this assay. Hence, it is important to ensure that the inhibition of proliferation 
does not mask the effects of potential PPAR agonists. 
Table 4.4 Cytotoxicity IC50 values for sargahydroquinoic acid (3.6), sargaquinoic acid 
(3.1), sargachromenoic acid (3.9) and sarganaphthoquinone (3.10) against 
Chang Liver and 3T3-L1 cell lines 
Compound 
Code  
Chang Liver 
IC50 (µg/mL) 
3T3-L1 
IC50 (µg/mL) 
Selectivity index 
(Chang/3T3-L1) 
3.6 43.16 5.45 7.9 
3.1 92.85 11.55 8.0 
3.9 53.56 11.4 4.7 
3.10 43.50 20.63 2.1 
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The relatively strong cytotoxicity of these compounds toward proliferating 3T3-L1 cells 
(Table 4.4 and Figure 4.5) raised the concern that this effect could override any PPAR 
activity.  For that reason, we defined the lowest toxic dose of the test compounds and used 
that concentration as a starting point for our anti-diabetic assay. Therefore, it was decided to 
test for 3T3-L1 differentiation at concentrations 10μg/mL and below. 
3.10 3.6
3.1 3.9
 
Figure 4.5 Dose dependent inhibition of proliferating 3T3-L1 cell viability by 
sargahydroquinoic acid (3.6), sargaquinoic acid (3.1), sargachromenoic acid 
(3.9) and sarganaphthoquinoic acid (3.10) 
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4.2.4 3T3-L1 preadipocyte differentiation assay 
The potential anti-diabetic (insulinomimetic) activity of sargahydroquinoic acid (3.6), 
sargaquinoic acid (3.1), sargachromenoic acid (3.9) and sarganaphthoquinoic acid (3.10) was 
evaluated using the 3T3-L1 preadipocyte differentiation assay (Figure 4.6 and 4.7). Despite 
previously raised concerns regarding the cytotoxicity of these test compounds towards 3T3-
L1 cells, there was an appreciable increase in the relative accumulation of triglycerides in the 
adipocytes, indicating positive interaction with the PPARγ.  It appears that proliferating and 
pre-growth arrested cells are more sensitive to the toxic effects of these compounds.  In future 
it would be advisable to simultaneously assess the relative cell density so as to exclude 
potential toxicity.  The most significant response was obtained from sarganaphthoquinoic 
acid (3.10). At test concentrations of 1 µg/mL (0.24 µM) and 5 µg/mL (1.19 µM), 
sarganaphthoquinoic acid (3.10) produced a response similar to that of rosiglitazone at 1 µM. 
Sargachromenoic acid (3.9) also induced a strong PPARγ response but it was only significant 
at 5 µg/mL (1.14 µM). The PPARγ activity of sargahydroquinoic acid (3.6) was weakly 
positive at 5 µg/mL (1.17 µM) while sargaquinoic acid (3.1) did not reveal any potential 
PPARγ activity at all test concentrations. The absence of any PPARγ activity with SQA 
conflicts with earlier research done by Kim et al. in which both SHQA and SQA produced 
very significant PPARγ mediated preadipocyte differentiation (Kim et al. 2008). However, 
considering that Kim et al. used 10 µM each of SHQA and SQA for the induction of 
differentiation while we used a maximum of 1.17 µM of SHQA and 1.18 µM of SQA, it is 
highly possible that increasing the test concentrations would also result in an increased 
PPARγ activity of these compounds. Even then, this still implies that sarganaphthoquinoic 
acid (3.10) is a more superior PPARγ agonist than SHQA and SQA. To our knowledge, this 
is the first report on the PPARγ-mediated anti-diabetic activity of sarganaphthoquinoic acid 
(3.10). In an attempt to improve the side effect profiles of current PPARγ agonists, research 
has explored the replacement of the thiazolidine ring with other ‘acidic head groups’ which 
have lesser side effects. Such examples include a study performed by Sundriyal et al. (2008) 
in which, after replacement of the thiazolidine ring with a 1,4-naphthoquinone moiety, the 
newly synthesized compounds still retained PPARγ activity comparable to pioglitazone 
(Sundriyal et al. 2008). This shows that the 1,4-naphthoquinone, sarganaphthoquinoic acid 
(3.10), is a potential PPARγ agonist which may have lesser side effects compared to current 
thiazolidinediones. Also, 1,4-naphthoquinones are commercially available, less costly and 
easily derivatized. 
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Figure 4.6 Dose dependent lipid accumulation in differentiating 3T3-L1 cells after treatment with sargahydroquinoic acid (3.6), sargaquinoic 
acid (3.1), sargachromenoic acid (3.9), sarganaphthoquinoic acid (3.10) and positive controls rosiglitazone and troglitazone
5
 
                                                          
5
 Each data point represents the mean±STDev for triplicate wells of a single experiment while the astericks (*) indicate a significant increase in lipid accumulation. 
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Figure 4.7 Representative images of oil Red O stained 3T3-L1 cells after treatment with 
sargahydroquinoic acid (3.6), sargaquinoic acid (3.1), sargachromenoic acid 
(3.9), sarganaphthoquinoic acid (3.10) and rosiglitazone 
In this chapter, after exploring the potential anti-oxidant/radical scavenging activity and anti-
inflammatory activity of S. heterophyllum fractions and pure natural products, SHQA (3.6, 
IC50 = 6.20 µg/mL) and sargachromenoic acid (3.9, IC50 = 6.99 µg/mL) exhibited the most 
potent DPPH radical scavenging activity while the fractions 64d (SHQA) and 64f 
(fucoxanthin) produced the most significant anti-inflammatory activity. After investigating 
the potential anti-diabetic activity of SHQA and synthetic derivatives, sarganaphthoquinoic 
acid (3.10) had the most significant PPARγ-mediated response similar to that of 
rosiglitazone. Sargachromenoic acid (3.9) also induced a strong response while that of 
sargahydroquinoic acid (3.6) was weakly positive compared to results earlier documented by 
Kim et al. (2008). It is however important to note that Kim et al. used a different protocol to 
investigate differentiation. The protocol implemented by Kim et al. used a combination of 
insulin (INS), 3-isobutyl-1-methylxanthin (IBMX) and dexamethasone (DEX) which is likely 
to amplify the induction of differentiation due to PPARγ activation through an indirect 
increase in PPARγ expression and not receptor-ligand binding. From a theoretic point of 
view, it is not an absolute requirement to include INS/IBMX/DEX as is evident in the 
positive controls we used which, in my opinion, represents a more direct evaluation of 
PPARγ activation. 
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4.3 Experimental 
4.3.1 General experimental procedures 
The culture mediums were sourced from Sigma Aldrich
®
 (South Africa) and Hyclone
® 
(Thermal Fisher, USA). The IC50 values of the test compounds were calculated from a 
minimum 5-point dose response curve using GraphPad Prism 4 software package. 
4.3.2 DPPH radical scavenging assay 
Test samples were diluted in ethanol/water (1:1) from 10 mg/100 µL stocks prepared in 
DMSO. 5 μL of each sample was placed into each well of a 96-well plate followed by the 
addition of 120 μL of Tris-HCl buffer (50 mM, pH7.4) and 120 μL of freshly prepared DPPH 
solution (0.1 mM in ethanol). The plate was incubated for 20 minutes at room temperature 
with the absorbance read at 513nm. The percentage of DPPH radical scavenging was 
calculated as [(A- B/A) × 100] where A represents the absorbance in the absence of test 
samples and B represents the absorbance in the presence of test samples. Ascorbic acid was 
used as a positive control (EC50 = 24.07μg/mL). 
4.3.3 Anti-inflammatory assays 
Anti-inflammatory assays were performed as previously reported in Chapter 2, Section 2.6.6. 
4.3.4 Cytotoxicity assays 
3T3-L1 cells were seeded into 96-well culture plates (TTP) at 3 000 cells/well in DMEM 
supplemented with10% fetal bovine serum (FBS) and left for 24 hrs. Test compounds were 
added and the cells incubated for a further 48 hrs after which the medium was replaced with 
200 μL of MTT (0.5 mg/mL in DMEM). Samples were then incubated for 3 hr at 37°C after 
which MTT was removed and the purple formazan product dissolved in 200 μL DMSO. 
Absorbance was measured at 560 nm using a multiwell scanning spectrophotometer 
(Multiscan MS, Labsystems). All incubation steps were carried out in a 37 °C humidified 
incubator with 5% CO2. Procedures for the cytotoxicity assays on Chang Liver cells were as 
previously reported in Chapter 2, Section 2.6.7. 
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4.3.5 3T3-L1 preadipocyte differentiation assay 
Prior to the induction of differentiation, 3T3-L1 cells were routinely maintained in DMEM 
containing new born calf serum. Cells were seeded at a density of 3000 cells/well into 96-
well plates and allowed to reach 100% confluence. Two days post-confluence, the cells were 
treated for a further two days with DMEM medium now supplemented with FBS (to induce 
mitotic clonal expansion) and the indicated concentrations of test compounds or the control 
substances rosiglitazone and troglitazone (1 μM, final concentration). Cells were then 
cultured for an additional 7 days in normal culture medium (DMEM, 10% FBS with 
inducers) and the medium replaced every two to three days. Triglyceride accumulation, a 
marker for adipocyte differentiation, was measured by Oil red-O staining. The Oil Red O 
stained lipids were extracted in isopropanol and measured at 510 nm. The sample results 
were then compared to controls using a two-tailed Student’s t-test assuming equal variances. 
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Chapter 5 
Conclusion 
Several studies have been done to search for terrestrial plant-derived natural products with 
potential anti-diabetic activity. However, there are very few studies that have embarked on 
investigating the potential anti-diabetic activity of marine algae. Through a literature review 
guided identification of specific marine algal genera and evaluation of their anti-oxidant 
activity, this research has shown that South African marine algae and specifically Sargassum 
heterophyllum (62) is a potentially good source of bioactive anti-oxidant compounds with 
higher potencies than conventional anti-oxidants. This research also serves as the first 
publication to document the anti-oxidant/radical scavenging activity of Bifurcariopsis 
capensis (8d). However, due to limitations of quantity, further isolation and characterization 
of the compounds responsible for the anti-oxidant activity of B. capensis (8d) was not 
undertaken. Taking into consideration that the DPPH radical scavenging/anti-oxidant assay 
that was employed uses a hydrogen atom transfer mechanism, further research may be 
improved by incorporating more biologically relevant anti-oxidant assays that mimic the 
electron transfer mechanism of biological systems. A good example of such is the cellular 
anti-oxidant assay (CAA) which also accounts for the uptake, metabolism and location of 
anti-oxidant compounds within cells. 
Despite relatively high in-vitro cytotoxicity profiles exhibited by S. heterophyllum extracts 
and crude fractions, the alga portrayed very interesting biological activity. The S. 
heterophyllum crude extract (62) as well as its metabolites sargahydroquinoic acid (3.6) and 
fucoxanthin (3.8) showed significant anti-inflammatory activity. Therefore, this research 
proves that in-vitro cytotoxicity assays should never be the only screening method to 
determine the selection of potentially bioactive crude extracts in-vivo. The in-vitro 
cytotoxicity of fucoxanthin (3.8) when directly applied to cultured cells, as was the case in 
our study, has been widely reported. It is known that fucoxanthin (3.8) undergoes enzymatic 
deacetylation in the intestinal lumen to form fucoxanthinol which is then further metabolized 
into amarouciaxanthin A in the liver. Fucoxanthinol and amarouciaxanthin A are the active 
but non cytotoxic forms of fucoxanthin in-vivo.  
In the evaluation of anti-diabetic (insulinomimetic) activity, sarganaphthoquinoic acid (3.10) 
showed the strongest PPARγ activity by producing a response similar to that of rosiglitazone 
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at 1 µM. Sargachromenoic acid (3.9) also induced a strong PPARγ response at 5 µg/mL. 
Sargachromenoic acid (3.9) exhibited significant anti-oxidant activity (IC50 = 6.99 µg/ml) in 
addition to PPARγ activity while sarganaphthoquinoic acid (3.10) did not show any anti-
oxidant activity. In Chapter one, we defined our ideal anti-diabetic agent as one that 
possesses anti-oxidant activity in addition to hypoglycaemic effects. By that definition, 
sargachromenoic acid (3.9) would appear to have more promise as an anti-diabetic agent than 
sarganaphthoquinoic acid (3.10). Further research may find it beneficial to evaluate the 
potential anti-inflammatory activity of the semi-synthetic derivatives which was not 
determined in this study. 
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Appendix I 
DPPH Radical Scavenging Activity 
 
Figure A1.1 Titration curves for DPPH radical scavenging activity of the crude extracts S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. 
capensis (8d), Sargassum sp. (8e) and S. heterophyllum (62) 
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Figure A1.2 Titration curves for the DPPH radical scavenging activity of Sargassum heterophyllum crude fractions (64a), (64b), (64c), (64d), 
(64e) and (64g) 
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3.10 3.6
3.1 3.9
 
Figure A1.3 Titration curves for DPPH radical scavenging activity of sarganaphthoquinoic 
acid (3.10), sargahydroquinoic acid (3.6), sargaquinoic acid (3.1) and 
sargachromenoic acid (3.9) 
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Appendix II 
Anti-inflammatory Assays 
 
Figure A2.1a Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions (64a), (64b), (64c) and (64d) 
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Figure A2.1b Nitrate production in mouse macrophages (RAW264.7) treated with S. heterophyllum fractions (64e), (64f), (64g) and (64i) 
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Appendix III 
Cytotoxicity Assays 
MN-11-8a MN-11-8b MN-11-8c
MN-11-8d MN-11-8e MN-11-62
 
Figure A3.1 Dose dependent inhibition of Chang liver cell viability by S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. capensis (8d), 
Sargassum sp. (8e) and S. heterophyllum (62) crude extracts 
109 
 
 
 
Figure A3.2 Dose dependent inhibition of HT-29 cell viability by S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. capensis (8d), Sargassum 
sp. (8e) and S. heterophyllum (62) crude extracts 
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Figure A3.3 Dose dependent inhibition of Caco-2 cell viability by S. zonale (8a), D. ligulata (8b), C. fibrosa (8c), B. capensis (8d), 
Sargassum sp. (8e) and S. heterophyllum (62) crude extracts 
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MN-11-64a MN-11-64b MN-11-64c
MN-11-64d MN-11-64e MN-11-64f
MN-11-64g MN-11-64h MN-11-64i
 
Figure A3.4 Dose dependent inhibition of Chang liver cell viability by S. heterophyllum fractions (64a), (64b), (64c), (64d), (64e), (64f), 
(64g), (64h) and (64i) 
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Figure A3.5 Dose dependent inhibition of HT-29 cell viability by S. heterophyllum fractions (64a), (64b), (64c), (64d), (64e), (64f), (64g), 
(64h) and (64i) 
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Figure A3.6 Dose dependent inhibition of Caco-2 cell viability by S. heterophyllum fractions (64a), (64b), (64c), (64d), (64e), (64f), (64g), 
(64h) and (64i) 
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Figure A3.7 Dose dependent inhibition of Chang liver cell viability by 
sarganaphthoquinoic acid (3.10), sargahydroquinoic acid (3.6), sargaquinoic 
acid (3.1) and sargachromenoic acid (3.9) 
 
